Movatterモバイル変換

[0]ホーム
URL:

DK0979281T3 - Process for the preparation of multispecific antibodies with heteromultimers and common components - Google Patents

Process for the preparation of multispecific antibodies with heteromultimers and common components

Info

Publication number
DK0979281T3
DK0979281T3DK98920059TDK98920059TDK0979281T3DK 0979281 T3DK0979281 T3DK 0979281T3DK 98920059 TDK98920059 TDK 98920059TDK 98920059 TDK98920059 TDK 98920059TDK 0979281 T3DK0979281 T3DK 0979281T3
Authority
DK
Denmark
Prior art keywords
polypeptide
interface
heteromultimers
formation
antibody
Prior art date
Application number
DK98920059T
Other languages
Danish (da)
Inventor
Robert Arathoon
Paul J Carter
Anne M Merchant
Leonard G Presta
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech IncfiledCriticalGenentech Inc
Application grantedgrantedCritical
Publication of DK0979281T3publicationCriticalpatent/DK0979281T3/en

Links

Classifications

Landscapes

Abstract

The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method provides a multispecific antibody having a common light chain associated with each heteromeric polypeptide having an antibody binding domain. Additionally the method further involves introducing into the multispecific antibody a specific and complementary interaction at the interface of a first polypeptide and the interface of a second polypeptide, so as to promote heteromultimer formation and hinder homomultimer formation; and/or a free thiol-containing residue at the interface of a first polypeptide and a corresponding free thiol-containing residue in the interface of a second polypeptide, such that a non-naturally occurring disulfide bond is formed between the first and second polypeptide. The method allows for the enhanced formation of the desired heteromultimer relative to undesired heteromultimers and homomultimers.
DK98920059T1997-05-021998-04-30 Process for the preparation of multispecific antibodies with heteromultimers and common componentsDK0979281T3 (en)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
US85005897A1997-05-021997-05-02
US5066197P1997-06-241997-06-24

Publications (1)

Publication NumberPublication Date
DK0979281T3true DK0979281T3 (en)2005-11-21

Family

ID=26728503

Family Applications (1)

Application NumberTitlePriority DateFiling Date
DK98920059TDK0979281T3 (en)1997-05-021998-04-30 Process for the preparation of multispecific antibodies with heteromultimers and common components

Country Status (11)

CountryLink
US (2)US8642745B2 (en)
EP (1)EP0979281B1 (en)
JP (2)JP4213224B2 (en)
AT (1)ATE299938T1 (en)
AU (1)AU751659B2 (en)
CA (1)CA2288600C (en)
DE (1)DE69830901T2 (en)
DK (1)DK0979281T3 (en)
ES (1)ES2246069T3 (en)
IL (1)IL132560A0 (en)
WO (1)WO1998050431A2 (en)

Families Citing this family (709)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US5731168A (en)1995-03-011998-03-24Genentech, Inc.Method for making heteromultimeric polypeptides
PT1157041E (en)*1999-03-012005-10-31Genentech Inc ANTIBODIES FOR CANCER THERAPY AND DIAGNOSIS
SI1157041T1 (en)*1999-03-012005-12-31Genentech IncAntibodies for cancer therapy and diagnosis
EP1074563A1 (en)*1999-08-022001-02-07F. Hoffmann-La Roche AgChimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof
SE0000597D0 (en)*2000-02-242000-02-24Active Biotech Ab Novel antibody
AU5720601A (en)*2000-04-262001-11-07Elusys Therapeutics IncBispecific molecules and uses thereof
ES2727425T3 (en)2000-12-122019-10-16Medimmune Llc Molecules with prolonged half-lives, compositions and uses thereof
RU2316337C2 (en)2001-04-242008-02-10Мерк Патент ГмбхCombined therapy by using antiangiogenic agents and tnf-alpha
EP1500665B1 (en)2002-04-152011-06-15Chugai Seiyaku Kabushiki KaishaMETHODS FOR CONSTRUCTING scDb LIBRARIES
AU2003235833A1 (en)2002-04-262003-11-10Chugai Seiyaku Kabushiki KaishaMethod of screening agonistic antibody
USRE47770E1 (en)2002-07-182019-12-17Merus N.V.Recombinant production of mixtures of antibodies
CA2872136C (en)*2002-07-182017-06-20Merus B.V.Recombinant production of mixtures of antibodies
AU2013200009B2 (en)*2002-07-182015-05-07Merus N.V.Recombinant production of mixtures of antibodies
EP1605058B1 (en)*2003-01-212009-05-13Chugai Seiyaku Kabushiki KaishaMethod of screening light chain of antibody light chains
EP2395016A3 (en)2003-05-302012-12-19Merus B.V.Design and use of paired variable regions of specific binding molecules
US20100069614A1 (en)2008-06-272010-03-18Merus B.V.Antibody producing non-human mammals
WO2005042582A1 (en)*2003-11-042005-05-12Chugai Seiyaku Kabushiki KaishaProcess for producing antibody
WO2004111233A1 (en)2003-06-112004-12-23Chugai Seiyaku Kabushiki KaishaProcess for producing antibody
AU2003271174A1 (en)2003-10-102005-04-27Chugai Seiyaku Kabushiki KaishaDouble specific antibodies substituting for functional protein
TW200530269A (en)2003-12-122005-09-16Chugai Pharmaceutical Co LtdAnti-Mpl antibodies
NZ548828A (en)2004-01-202009-07-31Merus B VMixtures of binding proteins
EP1765398B1 (en)*2004-06-012011-07-13Merck Sharp & Dohme Corp.Human antibodies interacting with hiv gp41
WO2006106905A1 (en)2005-03-312006-10-12Chugai Seiyaku Kabushiki KaishaProcess for production of polypeptide by regulation of assembly
WO2006106903A1 (en)2005-03-312006-10-12Chugai Seiyaku Kabushiki Kaishasc(Fv)2 STRUCTURAL ISOMERS
DK2824183T3 (en)*2005-04-082020-09-28Chugai Pharmaceutical Co Ltd Process for the production of bispecific antibodies
US9241994B2 (en)2005-06-102016-01-26Chugai Seiyaku Kabushiki KaishaPharmaceutical compositions containing sc(Fv)2
CN101237890A (en)2005-06-102008-08-06中外制药株式会社Stabilizer for protein preparation comprising meglumine and use thereof
TW200732350A (en)2005-10-212007-09-01Amgen IncMethods for generating monovalent IgG
ES2521679T3 (en)2006-01-182014-11-13Merck Patent Gmbh Specific therapy using integrin ligands for cancer treatment
EP2006381B1 (en)2006-03-312016-02-03Chugai Seiyaku Kabushiki KaishaMethod for controlling blood pharmacokinetics of antibodies
EP2009101B1 (en)2006-03-312017-10-25Chugai Seiyaku Kabushiki KaishaAntibody modification method for purifying bispecific antibody
WO2007115953A1 (en)*2006-04-072007-10-18Novo Nordisk Health Care AgCovalent factor vii-tissue factor complex
WO2007145840A2 (en)2006-06-132007-12-21Oncomed Pharmaceuticals, Inc.Compositions and methods for diagnosing and treating cancer
EP2035456A1 (en)*2006-06-222009-03-18Novo Nordisk A/SProduction of bispecific antibodies
EP2035452B1 (en)2006-06-222012-04-25Novo Nordisk A/SSoluble heterodimeric receptors and uses thereof
JP5087625B2 (en)2006-09-012012-12-05セラピューティック・ヒューマン・ポリクローナルズ・インコーポレーテッド Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
ME02371B (en)2006-09-292016-06-20Oncomed Pharm IncCompositions and methods for diagnosing and treating cancer
WO2008087025A2 (en)2007-01-182008-07-24Merck Patent GmbhSpecific therapy and medicament using integrin ligands for treating cancer
EP2125887A4 (en)2007-01-242010-11-10Oncomed Pharm IncCompositions and methods for diagnosing and treating cancer
ES2667863T3 (en)2007-03-292018-05-14Genmab A/S Bispecific antibodies and their production methods
ES2566957T3 (en)2007-09-262016-04-18Chugai Seiyaku Kabushiki Kaisha Constant region of modified antibody
JP5334319B2 (en)2007-09-262013-11-06中外製薬株式会社 Method for modifying isoelectric point of antibody by amino acid substitution of CDR
AU2008312937B2 (en)2007-10-152015-01-22Chugai Seiyaku Kabushiki KaishaMethod for production of antibody
US20090162359A1 (en)2007-12-212009-06-25Christian KleinBivalent, bispecific antibodies
AU2008346734A1 (en)2008-01-032009-07-16The Scripps Research InstituteAntibody targeting through a modular recognition domain
US8454960B2 (en)2008-01-032013-06-04The Scripps Research InstituteMultispecific antibody targeting and multivalency through modular recognition domains
US8557242B2 (en)2008-01-032013-10-15The Scripps Research InstituteERBB2 antibodies comprising modular recognition domains
US8574577B2 (en)2008-01-032013-11-05The Scripps Research InstituteVEGF antibodies comprising modular recognition domains
US8557243B2 (en)2008-01-032013-10-15The Scripps Research InstituteEFGR antibodies comprising modular recognition domains
CN107469077A (en)2008-04-112017-12-15中外制药株式会社The antigen binding molecules combined repeatedly with the antigen of multiple molecules
KR20110029156A (en)2008-06-272011-03-22메뤼스 베.페. Antibody Production Non-Human Mammals
CN102316897B (en)2008-07-082014-11-05昂考梅德药品有限公司 Notch binders and antagonists and methods of use thereof
US9132189B2 (en)2008-07-082015-09-15Oncomed Pharmaceuticals, Inc.Notch1 binding agents and methods of use thereof
US8652843B2 (en)2008-08-122014-02-18Oncomed Pharmaceuticals, Inc.DDR1-binding agents and methods of use thereof
US8298533B2 (en)2008-11-072012-10-30Medimmune LimitedAntibodies to IL-1R1
WO2010068722A1 (en)2008-12-122010-06-17Medimmune, LlcCrystals and structure of a human igg fc variant with enhanced fcrn binding
EP2409991B1 (en)2009-03-192017-05-03Chugai Seiyaku Kabushiki KaishaAntibody constant region variant
TWI682995B (en)2009-03-192020-01-21日商中外製藥股份有限公司 Antibody constant region alteration
EP2414391B1 (en)2009-04-022018-11-28Roche Glycart AGMultispecific antibodies comprising full length antibodies and single chain fab fragments
US9067986B2 (en)2009-04-272015-06-30Oncomed Pharmaceuticals, Inc.Method for making heteromultimeric molecules
BRPI1011206A2 (en)2009-05-252016-03-15Merck Patent Gmbh continuous administration of integrin ligands to treat cancer
US9676845B2 (en)2009-06-162017-06-13Hoffmann-La Roche, Inc.Bispecific antigen binding proteins
PT2564695E (en)2009-07-082015-06-03Kymab LtdAnimal models and therapeutic molecules
CA2781519A1 (en)2009-09-162011-03-24Genentech, Inc.Coiled coil and/or tether containing protein complexes and uses thereof
JP5837821B2 (en)2009-09-242015-12-24中外製薬株式会社 Antibody constant region variants
EP3485908B1 (en)2009-10-162021-08-18Mereo BioPharma 5, Inc.Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
AR078377A1 (en)2009-12-112011-11-02Genentech Inc ANTI-VEGF-C ANTIBODIES (ISOLATED ANTI-VASCULAR ENDOTELIAL GROWTH FACTOR C) AND ITS METHODS OF USE
KR20120107503A (en)2009-12-232012-10-02제넨테크, 인크.Anti-bv8 antibodies and uses thereof
PL2522724T3 (en)2009-12-252020-07-13Chugai Seiyaku Kabushiki KaishaPolypeptide modification method for purifying polypeptide multimers
AU2010344596B2 (en)2010-01-292013-08-01Toray Industries, Inc.Polylactic acid-based resin sheet
US20120021409A1 (en)2010-02-082012-01-26Regeneron Pharmaceuticals, Inc.Common Light Chain Mouse
PT2505654T (en)2010-02-082016-11-18Regeneron Pharma COMMON LIGHT CHAIN MOUSE
US20130045492A1 (en)2010-02-082013-02-21Regeneron Pharmaceuticals, Inc.Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en)2010-02-082017-10-24Regeneron Pharmaceuticals, Inc.Mice expressing a limited immunoglobulin light chain repertoire
US10435458B2 (en)2010-03-042019-10-08Chugai Seiyaku Kabushiki KaishaAntibody constant region variants with reduced Fcgammar binding
AR080793A1 (en)2010-03-262012-05-09Roche Glycart Ag BISPECIFIC ANTIBODIES
KR101930964B1 (en)2010-04-202018-12-19젠맵 에이/에스Heterodimeric antibody fc-containing proteins and methods for production thereof
MX346731B (en)2010-04-232017-03-30Genentech Inc *Production of heteromultimeric proteins.
US20120100166A1 (en)2010-07-152012-04-26Zyngenia, Inc.Ang-2 Binding Complexes and Uses Thereof
CA2805338A1 (en)2010-07-162012-01-19Merck Patent GmbhPeptide for use in the treatment of breast cancer and/or bone metastases
DK3029066T3 (en)2010-07-292019-05-20Xencor Inc ANTIBODIES WITH MODIFIED ISOELECTRIC ITEMS
MX2013001267A (en)2010-08-132013-04-10Genentech IncAntibodies to il-1beta and il-18, for treatment of disease.
DK2606064T3 (en)2010-08-162015-04-20Novimmune Sa Methods for generating multispecific and multivalent antibodies
CA2807278A1 (en)2010-08-242012-03-01F. Hoffmann - La Roche AgBispecific antibodies comprising a disulfide stabilized - fv fragment
US8551479B2 (en)2010-09-102013-10-08Oncomed Pharmaceuticals, Inc.Methods for treating melanoma
TWI629355B (en)*2010-11-172018-07-11中外製藥股份有限公司 Multispecific antigen-binding molecule capable of replacing blood coagulation factor VIII
BR112013013354A2 (en)2010-11-302020-10-06Chugai Seiyaku Kabushiki Kaisha antigen-binding molecule capable of binding to a plurality of antigen molecules repeatedly
KR20240025059A (en)2010-11-302024-02-26추가이 세이야쿠 가부시키가이샤Cytotoxicity-inducing therapeutic agent
JP5766296B2 (en)2010-12-232015-08-19エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Polypeptide-polynucleotide complexes and their use in targeted delivery of effector components
AR085138A1 (en)2011-02-042013-09-11Genentech Inc Fc VARIATIONS AND METHODS FOR PRODUCTION
US10689447B2 (en)2011-02-042020-06-23Genentech, Inc.Fc variants and methods for their production
MX342034B (en)2011-02-282016-09-12Hoffmann La RocheMonovalent antigen binding proteins.
CA2825081A1 (en)2011-02-282012-09-07Birgit BossenmaierAntigen binding proteins
US9499605B2 (en)2011-03-032016-11-22Zymeworks Inc.Multivalent heteromultimer scaffold design and constructs
WO2012122512A1 (en)2011-03-102012-09-13Hco Antibody, Inc.Recombinant production of mixtures of single chain antibodies
WO2012122528A1 (en)2011-03-102012-09-13Hco Antibody, Inc.Bispecific three-chain antibody-like molecules
KR20140019385A (en)2011-03-172014-02-14라모트 앳 텔-아비브 유니버시티 리미티드Bi- and monospecific, asymmetric antibodies and methods of generating the same
EA201791693A1 (en)2011-03-252018-05-31Гленмарк Фармасьютикалс С.А. HETERODIMERNY IMMUNOHLOBULINS
ES2704038T3 (en)2011-05-242019-03-13Zyngenia Inc Multivalent and monovalent multispecific complexes and their uses
GB201109965D0 (en)2011-06-102011-07-27Cancer Res Inst RoyalMaterials and methods for treating estrogen receptor alpher(ER) positive cancer
GB201109966D0 (en)2011-06-102011-07-27Cancer Res Inst RoyalMaterials and methods for treating pten mutated or deficient cancer
CA2840461A1 (en)2011-06-202012-12-27Kyowa Hakko Kirin Co., Ltd.Anti-erbb3 antibody
US9890218B2 (en)2011-06-302018-02-13Chugai Seiyaku Kabushiki KaishaHeterodimerized polypeptide
UA117901C2 (en)2011-07-062018-10-25Ґенмаб Б.В. METHOD FOR STRENGTHENING THE EFFECTORAL FUNCTION OF THE ORIGINAL POLYEPEPTIDE, ITS OPTIONS AND THEIR APPLICATIONS
KR20140053991A (en)2011-07-182014-05-08아츠 바이올로직스 에이/에스Long acting luteinizing hormone (lh) compound
FI3865581T3 (en)2011-08-052024-11-02Regeneron Pharma Humanized universal light chain mice
CN103889452B (en)2011-08-232017-11-03罗切格利卡特公司 Bispecific antibody specific for T cell activating antigen and tumor antigen and method of use
EP2757875B2 (en)2011-09-192023-03-22Kymab LimitedManipulation of immunoglobulin gene diversity and multi-antibody therapeutics
EP3485903B1 (en)2011-09-232022-11-16Mereo BioPharma 5, Inc.Vegf/dll4 binding agents and uses thereof
CA2791109C (en)2011-09-262021-02-16Merus B.V.Generation of binding molecules
US10851178B2 (en)2011-10-102020-12-01Xencor, Inc.Heterodimeric human IgG1 polypeptides with isoelectric point modifications
MX359384B (en)2011-10-112018-09-25Genentech IncImproved assembly of bispecific antibodies.
EA030440B1 (en)2011-10-242018-08-31Галозим, Инк.Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
JP6475017B2 (en)*2011-10-272019-02-27ゲンマブ エー／エス Production of heterodimeric protein
RU2681885C2 (en)2011-10-312019-03-13Чугаи Сейяку Кабусики КайсяAntigen-binding molecule having regulated conjugation between heavy-chain and light-chain
ES2816078T3 (en)2011-12-202021-03-31Medimmune Llc Modified Polypeptides for Bispecific Antibody Scaffolds
HK1200849A1 (en)*2011-12-222015-08-14F. Hoffmann-La Roche AgFull length antibody display system for eukaryotic cells and its use
RU2644341C2 (en)*2012-02-102018-02-08Дженентек, Инк.Single-chain antibodies and other heteromultimers
WO2013138681A1 (en)2012-03-162013-09-19Regeneron Pharmaceuticals, Inc.Mice that produce antigen-binding proteins with ph-dependent binding characteristics
US20140013456A1 (en)2012-03-162014-01-09Regeneron Pharmaceuticals, Inc.Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
KR102228296B1 (en)2012-03-162021-03-17리제너론 파마슈티칼스 인코포레이티드Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
LT2825037T (en)2012-03-162019-08-12Regeneron Pharmaceuticals, Inc.Rodents expressing ph-sensitive immunoglobulin sequences
US10251377B2 (en)2012-03-282019-04-09Kymab LimitedTransgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
PE20142422A1 (en)2012-04-052015-01-21Hoffmann La Roche BI-SPECIFIC ANTIBODIES AGAINST HUMAN TWEAK AND HUMAN IL 17 AND USES OF THE SAME
CN114163530B (en)2012-04-202025-04-29美勒斯公司 Methods and means for producing immunoglobulin-like molecules
AU2013259276B2 (en)2012-05-102018-03-22Bioatla LlcMulti-specific monoclonal antibodies
JP6628966B2 (en)2012-06-142020-01-15中外製薬株式会社 Antigen binding molecule containing an altered Fc region
WO2014001325A1 (en)2012-06-272014-01-03F. Hoffmann-La Roche AgMethod for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
HK1207864A1 (en)2012-06-272016-02-12F. Hoffmann-La Roche AgMethod for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
KR102090849B1 (en)2012-07-042020-03-19에프. 호프만-라 로슈 아게Covalently linked antigen-antibody conjugates
EP2869837B1 (en)2012-07-042016-09-14F. Hoffmann-La Roche AGAnti-theophylline antibodies and methods of use
KR20150030755A (en)2012-07-042015-03-20에프. 호프만-라 로슈 아게Anti-biotin antibodies and methods of use
EP2869845B1 (en)2012-07-062019-08-28Genmab B.V.Dimeric protein with triple mutations
EP3632462A1 (en)2012-07-062020-04-08Genmab B.V.Dimeric protein with triple mutations
IN2015DN01115A (en)2012-07-132015-06-26Zymeworks Inc
WO2014030728A1 (en)2012-08-242014-02-27中外製薬株式会社Fcγriib-specific fc region variant
HRP20181717T1 (en)2012-09-272018-12-28Merus N.V. BISPECIFIC IGG ANTIBODIES AS T STATION ACTIVATORS
US10087250B2 (en)2012-10-082018-10-02Roche Glycart AgFc-free antibodies comprising two fab-fragments and methods of use
US9278124B2 (en)2012-10-162016-03-08Halozyme, Inc.Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
US20140227252A1 (en)2012-10-312014-08-14Oncomed Pharmaceuticals , Inc.Methods and Monitoring of Treatment with a DLL4 Antagonist
CN110669136A (en)2012-11-052020-01-10全药工业株式会社Method for producing antibody or antibody composition
HK1211599A1 (en)2012-11-082016-05-27Eleven Biotherapeutics, Inc.Il-6 antagonists and uses thereof
US10766960B2 (en)2012-12-272020-09-08Chugai Seiyaku Kabushiki KaishaHeterodimerized polypeptide
JP6377635B2 (en)2013-01-102018-08-22ゲンマブ ビー．ブイ． Human IgG1 Fc region variants and uses thereof
US9701759B2 (en)2013-01-142017-07-11Xencor, Inc.Heterodimeric proteins
US11053316B2 (en)2013-01-142021-07-06Xencor, Inc.Optimized antibody variable regions
US10131710B2 (en)2013-01-142018-11-20Xencor, Inc.Optimized antibody variable regions
US10968276B2 (en)2013-03-122021-04-06Xencor, Inc.Optimized anti-CD3 variable regions
US9605084B2 (en)2013-03-152017-03-28Xencor, Inc.Heterodimeric proteins
DK2943511T3 (en)2013-01-142019-10-21Xencor Inc NEW HETERODIMERIC PROTEINS
US10487155B2 (en)2013-01-142019-11-26Xencor, Inc.Heterodimeric proteins
WO2014113510A1 (en)2013-01-152014-07-24Xencor, Inc.Rapid clearance of antigen complexes using novel antibodies
EP2961773B1 (en)2013-02-262019-03-20Roche Glycart AGBispecific t cell activating antigen binding molecules
MY199162A (en)2013-02-262023-10-18Roche Glycart AgBispecific t cell activating antigen binding molecules
RS62304B1 (en)*2013-03-142021-09-30Macrogenics Inc BISPECIFIC MOLECULES WHICH ARE IMMUNOREACTIVE WITH IMMUNE EFFECTIVE CELLS EXPRESSING AN ACTIVATING RECEPTOR
CN105451767B (en)2013-03-152019-10-18泽恩格尼亚股份有限公司Multivalence and monovalent polyspecific compound and application thereof
US10858417B2 (en)2013-03-152020-12-08Xencor, Inc.Heterodimeric proteins
US10544187B2 (en)2013-03-152020-01-28Xencor, Inc.Targeting regulatory T cells with heterodimeric proteins
US10519242B2 (en)2013-03-152019-12-31Xencor, Inc.Targeting regulatory T cells with heterodimeric proteins
US10106624B2 (en)2013-03-152018-10-23Xencor, Inc.Heterodimeric proteins
PL2992010T3 (en)2013-04-292021-08-23F.Hoffmann-La Roche AgFc-receptor binding modified asymmetric antibodies and methods of use
SG11201508910WA (en)2013-04-292015-11-27Hoffmann La RocheFcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases
WO2014177460A1 (en)2013-04-292014-11-06F. Hoffmann-La Roche AgHuman fcrn-binding modified antibodies and methods of use
US9783593B2 (en)2013-05-022017-10-10Kymab LimitedAntibodies, variable domains and chains tailored for human use
US11707056B2 (en)2013-05-022023-07-25Kymab LimitedAnimals, repertoires and methods
RS60131B1 (en)2013-07-052020-05-29Genmab AsHumanized or chimeric cd3 antibodies
MX2016001165A (en)*2013-07-312016-06-29Amgen IncStabilization of fc-containing polypeptides.
KR102441231B1 (en)2013-09-272022-09-06추가이 세이야쿠 가부시키가이샤 Method for preparing polypeptide heteromultimers
EP3037525B1 (en)2013-09-302021-06-02Chugai Seiyaku Kabushiki KaishaMethod for producing antigen-binding molecule using modified helper phage
CA2925723A1 (en)2013-10-012015-04-09Kymab LimitedAnimal models and therapeutic molecules
EP3055329B1 (en)2013-10-112018-06-13F. Hoffmann-La Roche AGMultispecific domain exchanged common variable light chain antibodies
WO2015068847A1 (en)2013-11-112015-05-14中外製薬株式会社Antigen-binding molecule containing modified antibody variable region
RS60443B1 (en)2013-12-172020-07-31Genentech IncAnti-cd3 antibodies and methods of use
LT3083680T (en)2013-12-202020-04-10F. Hoffmann-La Roche AgHUMANIZED ANTI-Tau(pS422) ANTIBODIES AND METHODS OF USE
RU2016129517A (en)*2013-12-202018-01-25Ф. Хоффманн-Ля Рош Аг SPECIFIC ANTIBODIES TO HER2 AND METHODS OF APPLICATION
JP6476194B2 (en)2014-01-032019-02-27エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Bispecific anti-hapten / anti-blood brain barrier receptor antibodies, complexes thereof, and their use as blood brain barrier shuttles
MX373017B (en)2014-01-032020-04-28Hoffmann La Roche COVALENTLY LINKED POLYPEPTIDE TOXIN-ANTIBODY CONJUGATES.
WO2015101587A1 (en)2014-01-032015-07-09F. Hoffmann-La Roche AgCovalently linked helicar-anti-helicar antibody conjugates and uses thereof
ES2864160T3 (en)2014-01-062021-10-13Hoffmann La Roche Monovalent Blood Brain Barrier Shuttle Modules
CA2931986A1 (en)2014-01-152015-07-23F. Hoffmann-La Roche AgFc-region variants with modified fcrn- and maintained protein a-binding properties
CR20160379A (en)2014-02-212016-10-07Genentech Inc BISPECIFIC ANTIBODIES ANTI-IL 13 / IL-17 AND ITS USES
LT3110849T (en)2014-02-282020-12-10Merus N.V.Antibody that binds erbb-2 and erbb-3
NZ724013A (en)2014-02-282019-11-29Merus NvAntibodies that bind egfr and erbb3
CA2941687A1 (en)2014-03-142015-09-17Genentech, Inc.Methods and compositions for secretion of heterologous polypeptides
WO2015143414A2 (en)2014-03-212015-09-24Regeneron Pharmaceuticals, Inc.Non-human animals that make single domain binding proteins
BR112016022385A2 (en)2014-03-282018-06-19Xencor, Inc specific antibodies that bind to cd38 and cd3
EP3825326A1 (en)*2014-04-012021-05-26Adimab, LLCMultispecific antibody analogs comprising a common light chain, and methods of their preparation and use
KR102376287B1 (en)2014-04-022022-03-17에프. 호프만-라 로슈 아게Method for detecting multispecific antibody light chain mispairing
UA117289C2 (en)2014-04-022018-07-10Ф. Хоффманн-Ля Рош Аг MULTISPECIFIC ANTIBODY
ES2900898T3 (en)2014-04-072022-03-18Chugai Pharmaceutical Co Ltd Bispecific immunoactivating antibodies
HRP20231139T1 (en)2014-05-062024-01-05F. Hoffmann - La Roche AgProduction of heteromultimeric proteins using mammalian cells
UA123986C2 (en)*2014-05-132021-07-07Дзе Трастіз Оф Дзе Юніверсіті Оф ПенсильваніяCompositions comprising aav expressing dual antibody constructs and uses thereof
JP6894702B2 (en)2014-05-132021-06-30中外製薬株式会社 T cell redirection antigen-binding molecule for cells with immunosuppressive function
AR100978A1 (en)2014-06-262016-11-16Hoffmann La Roche ANTI-Tau HUMANIZED ANTIBODY BRAIN LAUNCHERS (pS422) AND USES OF THE SAME
WO2015197736A1 (en)2014-06-262015-12-30F. Hoffmann-La Roche AgAnti-brdu antibodies and methods of use
IL296633A (en)2014-07-112022-11-01Genmab As Antibodies that bind axl
KR102067092B1 (en)2014-08-042020-01-17에프. 호프만-라 로슈 아게Bispecific t cell activating antigen binding molecules
EP2982692A1 (en)2014-08-042016-02-10EngMab AGBispecific antibodies against CD3epsilon and BCMA
BR112017003236A2 (en)2014-09-122017-11-28Genentech Inc cysteine engineered antibodies, drug conjugates and antibodies, drug and antibody conjugate preparation method and pharmaceutical composition
AU2015314954B2 (en)2014-09-122021-05-13Genentech, Inc.Anti-HER2 antibodies and immunoconjugates
CR20170095A (en)2014-09-122017-07-19Genentech Inc ANTI-CLL-1 ANTIBODIES AND IMMUNOCATE PLAYERS RECIPROCAL REFERENCES WITH RELATED APPLICATIONS
EP3197500A1 (en)2014-09-172017-08-02Genentech, Inc.Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines
TWI701435B (en)2014-09-262020-08-11日商中外製藥股份有限公司 Method to determine the reactivity of FVIII
TWI700300B (en)2014-09-262020-08-01日商中外製藥股份有限公司 Antibodies that neutralize substances with the function of FVIII coagulation factor (FVIII)
MA40764A (en)2014-09-262017-08-01Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENT INDUCING CYTOTOXICITY
BR112017006515A8 (en)2014-09-292018-02-27Univ Duke bispecific molecules, compositions, method for treating or preventing HIV-1 infection in an individual with this need, and vector
CA2963692A1 (en)2014-10-092016-04-14Engmab AgBispecific antibodies against cd3epsilon and ror1
CA3203273A1 (en)2014-10-142016-04-21Halozyme, Inc.Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
DK3212233T3 (en)2014-10-312020-07-27Oncomed Pharm Inc COMBINATION THERAPY FOR TREATMENT OF DISEASE
US11773166B2 (en)2014-11-042023-10-03Ichnos Sciences SACD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
AR102522A1 (en)2014-11-062017-03-08Hoffmann La Roche FC REGION VARIATIONS WITH MODIFIED PROPERTIES OF UNION TO FCRN AND PROTEIN A
CN107108720A (en)2014-11-062017-08-29豪夫迈·罗氏有限公司Fc region variants and its application method that FCRN with change is combined
HRP20191945T1 (en)2014-11-072020-01-24Sesen Bio, Inc. IMPROVED IL-6-ANTIBODIES
WO2016073894A1 (en)2014-11-072016-05-12Eleven Biotherapeutics, Inc.Therapeutic agents with increased ocular retention
KR20170080604A (en)2014-11-102017-07-10제넨테크, 인크.Anti-interleukin-33 antibodies and uses thereof
CN107250158B (en)2014-11-192022-03-25基因泰克公司Anti-transferrin receptor/anti-BACE 1 multispecific antibodies and methods of use
MX381724B (en)*2014-11-202025-03-13Hoffmann La Roche COMMON LIGHT CHAINS AND METHODS OF USE.
EP3023437A1 (en)2014-11-202016-05-25EngMab AGBispecific antibodies against CD3epsilon and BCMA
MA40972B1 (en)2014-11-202020-11-30Hoffmann La Roche Bispecific antigen binding molecules activating t cells targeting folr1 and cd3
MY192999A (en)2014-11-202022-09-20Hoffmann La RocheCombination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
US10259887B2 (en)2014-11-262019-04-16Xencor, Inc.Heterodimeric antibodies that bind CD3 and tumor antigens
ES2886523T3 (en)2014-11-262021-12-20Xencor Inc Heterodimeric antibodies that bind to CD3 and CD20
EA037065B1 (en)2014-11-262021-02-01Ксенкор, Инк.Heterodimeric antibodies that bind cd3 and cd38
JP6721590B2 (en)2014-12-032020-07-15エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Multispecific antibody
KR20170085595A (en)2014-12-102017-07-24제넨테크, 인크.Blood brain barrier receptor antibodies and methods of use
WO2016097300A1 (en)2014-12-192016-06-23Genmab A/SRodent bispecific heterodimeric proteins
PE20221834A1 (en)2014-12-192022-11-29Chugai Pharmaceutical Co Ltd ANTIMYOSTATIN ANTIBODIES
WO2016105450A2 (en)2014-12-222016-06-30Xencor, Inc.Trispecific antibodies
WO2016141387A1 (en)2015-03-052016-09-09Xencor, Inc.Modulation of t cells with bispecific antibodies and fc fusions
JP2018508224A (en)2015-03-192018-03-29リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Non-human animals that select light chain variable regions that bind antigen
EP3279216A4 (en)2015-04-012019-06-19Chugai Seiyaku Kabushiki Kaisha PROCESS FOR THE PRODUCTION OF A POLYPEPTIDE HETERO-OLIGOMER
CN107810012A (en)2015-06-022018-03-16豪夫迈·罗氏有限公司Use the composition and method of the anti-Antybody therapy sacred diseases of IL 34
EP3310814B1 (en)2015-06-162023-08-02F. Hoffmann-La Roche AGHumanized and affinity matured antibodies to fcrh5 and methods of use
EP3310378B1 (en)2015-06-162024-01-24F. Hoffmann-La Roche AGAnti-cll-1 antibodies and methods of use
WO2016207245A1 (en)2015-06-242016-12-29F. Hoffmann-La Roche AgHumanized anti-tau(ps422) antibodies and methods of use
EP3313890A1 (en)*2015-06-242018-05-02H. Hoffnabb-La Roche AgTrispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use
JP6892431B2 (en)2015-07-102021-06-23ゲンマブ エー／エス AXL-Specific Antibodies-Drug Conjugates for Cancer Treatment
DK3115376T3 (en)2015-07-102018-11-26Merus Nv HUMANT CD3 BINDING ANTIBODY
AU2016293073B2 (en)2015-07-152022-12-22Genmab A/SHumanized or chimeric CD3 antibodies
AU2016326609B2 (en)2015-09-232023-03-09Mereo Biopharma 5, Inc.Methods and compositions for treatment of cancer
AR106188A1 (en)2015-10-012017-12-20Hoffmann La Roche ANTI-CD19 HUMANIZED HUMAN ANTIBODIES AND METHODS OF USE
MA43345A (en)2015-10-022018-08-08Hoffmann La Roche PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
AR106199A1 (en)2015-10-022017-12-20Hoffmann La Roche T-CELL ACTIVATING ANTIGEN BINDING MOLECULES OF ANTIGEN
CR20180161A (en)2015-10-022018-05-25Hoffmann La Roche Bispecific Antibodies for PD1 and TIM3
WO2017055393A1 (en)2015-10-022017-04-06F. Hoffmann-La Roche AgAnti-cd3xtim-3 bispecific t cell activating antigen binding molecules
EP3150637A1 (en)2015-10-022017-04-05F. Hoffmann-La Roche AGMultispecific antibodies
WO2017055385A1 (en)2015-10-022017-04-06F. Hoffmann-La Roche AgAnti-cd3xgd2 bispecific t cell activating antigen binding molecules
US20180282410A1 (en)2015-10-022018-10-04Hoffmann-La Roche Inc.Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
BR112018000835A2 (en)2015-10-022018-09-11Hoffmann La Roche molecule, one or more polynucleotides, one or more vectors, cell, molecule production method, composition, use of the molecule, method of treating a disease and method for inducing lysis of a target cell
WO2017055392A1 (en)2015-10-022017-04-06F. Hoffmann-La Roche AgAnti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
JP6734919B2 (en)2015-10-022020-08-05エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Cell-based FRET assay for measuring simultaneous binding
EP3356417A1 (en)2015-10-022018-08-08H. Hoffnabb-La Roche AgBispecific t cell activating antigen binding molecules binding mesothelin and cd3
WO2017055314A1 (en)2015-10-022017-04-06F. Hoffmann-La Roche AgBispecific anti-cd19xcd3 t cell activating antigen binding molecules
RU2731202C2 (en)2015-10-082020-08-31Макродженикс, Инк.Combined therapy for cancer treatment
MA43354A (en)2015-10-162018-08-22Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
MA45326A (en)2015-10-202018-08-29Genentech Inc CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
BR112018008068A2 (en)2015-10-232018-11-13Merus N.V. binding molecules that inhibit cancer growth
EP3367786A1 (en)*2015-10-292018-09-05H. Hoffnabb-La Roche AgTransgenic rabbit with common light chain
WO2017072210A1 (en)2015-10-292017-05-04F. Hoffmann-La Roche AgAnti-variant fc-region antibodies and methods of use
TW201730211A (en)2015-10-302017-09-01建南德克公司Anti-Factor D antibodies and conjugates
JP6931329B2 (en)2015-11-182021-09-01中外製薬株式会社 Combination therapy using T cell redirection antigen-binding molecule for cells with immunosuppressive function
EP3378488A4 (en)2015-11-182019-10-30Chugai Seiyaku Kabushiki Kaisha METHOD FOR ENHANCING THE HUMORAL IMMUNE RESPONSE
BR112018011100A2 (en)2015-12-012018-12-04Genmab B.V. antibody, composition, nucleic acid construct, expression vector, host cell, method for treating an individual having a cancer, kit of parts, and use of an antibody or composition.
AU2016365742A1 (en)2015-12-072018-06-21Xencor, Inc.Heterodimeric antibodies that bind CD3 and PSMA
MX2018005229A (en)2015-12-092019-04-29F Hoffmann­La Roche Ag ANTIBODY ANTI-CD20 TYPE II AND USES OF THE SAME.
EP3178848A1 (en)2015-12-092017-06-14F. Hoffmann-La Roche AGType ii anti-cd20 antibody for reducing formation of anti-drug antibodies
EA201891420A1 (en)2015-12-182019-02-28Чугаи Сейяку Кабусики Кайся ANTIBODIES TO MYOSTATIN, POLYPEPTIDES, CONTAINING OPTIONS OF FC-REGIONS, AND METHODS OF THEIR APPLICATION
JP6954842B2 (en)2015-12-252021-10-27中外製薬株式会社 Antibodies with enhanced activity and methods for modifying them
BR112018009312A8 (en)2015-12-282019-02-26Chugai Pharmaceutical Co Ltd method for promoting purification efficiency of fc region-containing polypeptide
SG11201804961UA (en)2015-12-302018-07-30Genentech IncFormulations with reduced degradation of polysorbate
CN108430455A (en)2015-12-302018-08-21豪夫迈·罗氏有限公司 Use of tryptophan derivatives for protein formulations
BR112018011029A2 (en)2016-01-082018-11-21Hoffmann La Roche methods for treating or delaying cancer progression and improving immune function in a cancer individual, uses of a binding antagonist and a bispecific antibody, compositions and kits
CN108718522A (en)2016-02-232018-10-30赛森生物股份有限公司IL-6 antagonist formulations and application thereof
SG11201807936VA (en)2016-03-142018-10-30Chugai Pharmaceutical Co LtdCell injury inducing therapeutic drug for use in cancer therapy
FI3433280T3 (en)2016-03-222023-06-06Hoffmann La RocheProtease-activated t cell bispecific molecules
KR20250095754A (en)2016-04-152025-06-26알파인 이뮨 사이언시즈, 인코포레이티드Icos ligand variant immunomodulatory proteins and uses thereof
MA43552A (en)2016-04-152018-11-07Alpine Immune Sciences Inc CD80 VARIANT IMMUNOMODULATOR PROTEINS AND THEIR USES
JP6675017B2 (en)2016-05-022020-04-01エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Contrast body-single chain target binding substance
WO2017201449A1 (en)2016-05-202017-11-23Genentech, Inc.Protac antibody conjugates and methods of use
JP7022080B2 (en)2016-05-272022-02-17ジェネンテック， インコーポレイテッド Biochemical analytical methods for the characterization of site-specific antibody-drug conjugates
EP3252078A1 (en)2016-06-022017-12-06F. Hoffmann-La Roche AGType ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
WO2018220099A1 (en)2017-06-022018-12-06F. Hoffmann-La Roche AgType ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
CN109476648B (en)2016-06-062022-09-13豪夫迈·罗氏有限公司Sevelamer antibody-drug conjugates and methods of use
HUE068801T2 (en)2016-06-142025-01-28Xencor IncBispecific checkpoint inhibitor antibodies
KR102306744B1 (en)2016-06-172021-09-28추가이 세이야쿠 가부시키가이샤Anti-myostatin antibodies and methods of use
WO2017218977A2 (en)2016-06-172017-12-21Genentech, Inc.Purification of multispecific antibodies
CN109715663B (en)2016-06-282022-11-25Xencor股份有限公司Heterodimeric antibodies binding to somatostatin receptor 2
CN119120423A (en)2016-07-012024-12-13分解治疗有限责任公司 Optimized dinuclease fusions and methods
JP6983824B2 (en)2016-07-042021-12-17エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft New antibody format
MA45672A (en)2016-07-142019-05-22Biontech Ag MULTISPECIFIC ANTIBODIES DIRECTED AGAINST CD40 AND CD137
WO2018014260A1 (en)2016-07-202018-01-25Nanjing Legend Biotech Co., Ltd.Multispecific antigen binding proteins and methods of use thereof
US11834490B2 (en)2016-07-282023-12-05Alpine Immune Sciences, Inc.CD112 variant immunomodulatory proteins and uses thereof
US11471488B2 (en)2016-07-282022-10-18Alpine Immune Sciences, Inc.CD155 variant immunomodulatory proteins and uses thereof
EP3491013A1 (en)2016-07-282019-06-05Alpine Immune Sciences, Inc.Cd155 variant immunomodulatory proteins and uses thereof
EP3496763A1 (en)2016-08-112019-06-19Genentech, Inc.Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
US10793632B2 (en)2016-08-302020-10-06Xencor, Inc.Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
BR112019003989A2 (en)2016-09-062019-05-28Chugai Pharmaceutical Co Ltd methods of using a bispecific antibody that recognizes coagulation factor ix and / or activated coagulation factor ix and coagulation factor x and / or coagulation factor x activated
MX2019002967A (en)2016-09-142019-07-04Teneobio Inc CD3 BINDING ANTIBODIES.
CN109791149A (en)2016-09-302019-05-21豪夫迈·罗氏有限公司The dual combination measuring method based on SPR for functional analysis multispecific molecule
ES2897217T3 (en)2016-09-302022-02-28Hoffmann La Roche Bispecific antibodies against p95HER2
JP7050770B2 (en)2016-10-052022-04-08エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Method for preparing antibody drug conjugate
WO2018068201A1 (en)2016-10-112018-04-19Nanjing Legend Biotech Co., Ltd.Single-domain antibodies and variants thereof against ctla-4
MY203000A (en)2016-10-142024-06-01Xencor IncIl15/il15r� heterodimeric fc-fusion proteins
WO2018083126A1 (en)2016-11-012018-05-11Genmab B.V.Polypeptide variants and uses thereof
TWI791471B (en)2016-11-152023-02-11美商建南德克公司Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
TW201829463A (en)2016-11-182018-08-16瑞士商赫孚孟拉羅股份公司 anti-HLA-G antibody and use thereof
MA46959A (en)2016-12-022019-10-09Juno Therapeutics Inc MODIFIED B CELLS AND RELATED COMPOSITIONS AND METHODS
AU2017382251B2 (en)2016-12-212025-01-23Teneobio, Inc.Anti-BCMA heavy chain-only antibodies
PE20191347A1 (en)2017-02-012019-09-30Novo Nordisk As PROCOAGULATING ANTIBODIES
CN110945021B (en)2017-02-102025-09-12根马布私人有限公司 Polypeptide variants and their uses
EP4527854A3 (en)2017-03-092025-06-25Genmab A/SAntibodies against pd-l1
NZ756132A (en)2017-03-102022-02-25Hoffmann La RocheMethod for producing multispecific antibodies
KR20190141146A (en)2017-03-162019-12-23알파인 이뮨 사이언시즈, 인코포레이티드 PD-L2 variant immunomodulatory protein and uses thereof
HRP20231382T1 (en)2017-03-162024-02-16Alpine Immune Sciences, Inc. PD-L1 VARIANT OF IMMUNOMODULATING PROTEINS AND THEIR USE
MX2019010887A (en)2017-03-162019-10-15Alpine Immune Sciences IncCd80 variant immunomodulatory proteins and uses thereof.
JP7050333B2 (en)2017-03-242022-04-08全薬工業株式会社 Anti-IgM / B cell surface antigen bispecific antibody
EP3601354A1 (en)2017-03-312020-02-05Genmab Holding B.V.Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
EP3600413A1 (en)2017-03-312020-02-05Merus N.V.Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
MA49289A (en)2017-04-032020-02-12Hoffmann La Roche ANTIBODIES BINDING TO STEAP-1
EP3606947B1 (en)2017-04-032022-12-21F. Hoffmann-La Roche AGImmunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
CA3053357A1 (en)2017-04-032018-10-11F. Hoffmann-La Roche AgImmunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
AU2018247797B2 (en)2017-04-052024-10-10F. Hoffmann-La Roche AgAnti-LAG3 antibodies
SG11201909154SA (en)2017-04-052019-10-30Hoffmann La RocheBispecific antibodies specifically binding to pd1 and lag3
TWI871272B (en)2017-04-112025-02-01美商因荷布瑞克斯生物科學公司Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
BR112019021411A2 (en)2017-04-132020-05-05Hoffmann La Roche methods to treat or slow the progression of cancer and to improve function, uses of an immunoconjugate, an agonist, an antagonist, compositions, kit and invention
ES2951864T3 (en)2017-05-172023-10-25Merus Nv Combination of an ERBB-2/ERBB-3 bispecific antibody with endocrine therapy for breast cancer
EP3630836A1 (en)*2017-05-312020-04-08Elstar Therapeutics, Inc.Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
KR20200027944A (en)2017-06-072020-03-13젠맵 비. 브이 Therapeutic antibody based on mutated IGG hexamer
BR112019026907A2 (en)2017-06-202020-06-30Teneobio, Inc. ANTIBODIES ONLY OF HEAVY CHAIN ANTI-BCMA, POLYNUCLEOTIDE, VECTOR, CELL, PHARMACEUTICAL COMPOSITION, ITS USES AND METHOD TO PRODUCE THE SAME
WO2018237006A1 (en)2017-06-202018-12-27Teneoone, Inc. ANTIBODIES ONLY TO HEAVY ANTI-BCMA CHAINS
GB201709970D0 (en)2017-06-222017-08-09Kymab LtdBispecific antigen-binding molecules
WO2019006472A1 (en)2017-06-302019-01-03Xencor, Inc.Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains
SG11202000014UA (en)2017-07-062020-01-30Merus NvBinding molecules that modulate a biological activity expressed by a cell
GB201710984D0 (en)2017-07-072017-08-23Kymab LtdCells, vertebrates, populations & methods
AR112603A1 (en)2017-07-102019-11-20Lilly Co Eli BIS SPECIFIC ANTIBODIES CONTROL POINT INHIBITORS
HRP20211744T1 (en)2017-07-142022-02-04Immatics Biotechnologies GmbhImproved dual specificity polypeptide molecule
DE102017115966A1 (en)2017-07-142019-01-17Immatics Biotechnologies Gmbh Polypeptide molecule with improved dual specificity
KR102758346B1 (en)2017-08-042025-01-24젠맵 에이/에스 Binding agent that binds to PD-L1 and CD137 and uses thereof
FI3665198T3 (en)2017-08-092025-04-25Merus NvAntibodies that bind egfr and cmet
KR102777015B1 (en)2017-08-222025-03-10사나바이오, 엘엘씨 Availability of interferon receptors and their uses
EP3457139A1 (en)2017-09-192019-03-20Promise Advanced ProteomicsAntibody-like peptides for quantifying therapeutic antibodies
JP6496095B1 (en)2017-09-292019-04-03中外製薬株式会社 Multispecific antigen-binding molecule having blood coagulation factor VIII (FVIII) cofactor function alternative activity and pharmaceutical preparation containing the molecule as an active ingredient
CN111801347A (en)2017-10-102020-10-20高山免疫科学股份有限公司CTLA-4 variant immunomodulatory proteins and uses thereof
TW202500579A (en)2017-10-182025-01-01美商艾爾潘免疫科學有限公司Variant icos ligand immunomodulatory proteins and related compositions and methods
CN111246885B (en)2017-10-202024-06-11豪夫迈·罗氏有限公司 Methods for generating multispecific antibodies from monospecific antibodies
JP7438942B2 (en)2017-10-302024-02-27エフ． ホフマン－ラ ロシュ アーゲー Methods for in vivo generation of multispecific antibodies from monospecific antibodies
TWI829658B (en)2017-11-012024-01-21瑞士商赫孚孟拉羅股份公司Bispecific 2+1 contorsbodies
MA50534A (en)2017-11-012020-09-09Chugai Pharmaceutical Co Ltd ANTIBODY VARIANT AND ISOFORM WITH REDUCED BIOLOGICAL ACTIVITY
WO2019089544A1 (en)2017-11-012019-05-09Tufts Medical Center, Inc.Bispecific antibody constructs and methods of use
CA3079129C (en)2017-11-012023-02-28F. Hoffmann-La Roche AgTrifab-contorsbody
EP3704150A1 (en)2017-11-012020-09-09F. Hoffmann-La Roche AGThe compbody - a multivalent target binder
WO2019086499A1 (en)2017-11-012019-05-09F. Hoffmann-La Roche AgNovel tnf family ligand trimer-containing antigen binding molecules
US10981992B2 (en)2017-11-082021-04-20Xencor, Inc.Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
JP7311425B2 (en)2017-11-082023-07-19協和キリン株式会社 Bispecific antibodies that bind to CD40 and EpCAM
EP3706793A1 (en)2017-11-082020-09-16Xencor, Inc.Bispecific and monospecific antibodies using novel anti-pd-1 sequences
SG11202005732XA (en)2017-12-192020-07-29Xencor IncEngineered il-2 fc fusion proteins
WO2019126398A1 (en)2017-12-192019-06-27Surrozen, Inc.Wnt surrogate molecules and uses thereof
CA3085596A1 (en)2017-12-192019-06-27Surrozen, Inc.Anti-frizzled antibodies and methods of use
CA3085785A1 (en)2017-12-192019-06-27Surrozen, Inc.Anti-lrp5/6 antibodies and methods of use
AU2018390881A1 (en)2017-12-212020-07-02F. Hoffmann-La Roche AgAntibodies binding to HLA-A2/WT1
DK3728328T5 (en)2017-12-222025-02-17Argenx Bvba Bispecific antigen-binding construct
WO2019122054A1 (en)2017-12-222019-06-27F. Hoffmann-La Roche AgDepletion of light chain mispaired antibody variants by hydrophobic interaction chromatography
AU2018395273A1 (en)2017-12-272020-08-13Teneobio, Inc.CD3-delta/epsilon heterodimer specific antibodies
TWI817974B (en)2017-12-282023-10-11日商中外製藥股份有限公司Cytotoxicity-inducing therapeutic agent
JP7369127B2 (en)2017-12-282023-10-25ナンジン レジェンド バイオテック カンパニー，リミテッド Single domain antibodies against TIGIT and variants thereof
EP3731864A1 (en)2017-12-292020-11-04F. Hoffmann-La Roche SAAnti-vegf antibodies and methods of use
EP3735417A1 (en)2018-01-032020-11-11Alpine Immune Sciences, Inc.Multi-domain immunomodulatory proteins and methods of use thereof
EP3740507A4 (en)2018-01-152022-08-24Nanjing Legend Biotech Co., Ltd. SINGLE-DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST PD-1
JP2021510740A (en)2018-01-242021-04-30ゲンマブ ビー．ブイ． Polypeptide variants and their uses
CN111655730A (en)2018-01-312020-09-11豪夫迈·罗氏有限公司 Bispecific antibodies comprising an antigen-binding site that binds to LAG3
WO2019149715A1 (en)2018-01-312019-08-08F. Hoffmann-La Roche AgStabilized immunoglobulin domains
CN111699004A (en)2018-02-062020-09-22豪夫迈·罗氏有限公司Treatment of ophthalmic disorders
CA3089287A1 (en)2018-02-082019-08-15Genentech, Inc.Bispecific antigen-binding molecules and methods of use
TWI829667B (en)2018-02-092024-01-21瑞士商赫孚孟拉羅股份公司Antibodies binding to gprc5d
EP3762406A2 (en)2018-03-092021-01-13Askgene Pharma, Inc.Cytokine prodrugs
CN111971298B (en)2018-03-122025-06-20健玛保 Antibody
KR20200135510A (en)2018-03-292020-12-02제넨테크, 인크. Regulation of lactation stimulating activity in mammalian cells
US11952424B2 (en)2018-03-302024-04-09Merus N.V.Multivalent antibody
JP7346790B2 (en)2018-03-302023-09-20ナンジン レジェンド バイオテック カンパニー，リミテッド Single domain antibodies against LAG-3 and their uses
EP3773911A2 (en)2018-04-042021-02-17Xencor, Inc.Heterodimeric antibodies that bind fibroblast activation protein
SG11202009804RA (en)2018-04-112020-11-27Inhibrx IncMultispecific polypeptide constructs having constrained cd3 binding and related methods and uses
JP2021521784A (en)2018-04-182021-08-30ゼンコア インコーポレイテッド PD-1 targeted heterodimer fusion proteins containing IL-15 / IL-15RaFc fusion proteins and PD-1 antigen binding domains and their use
AR114789A1 (en)2018-04-182020-10-14Hoffmann La Roche ANTI-HLA-G ANTIBODIES AND THE USE OF THEM
AR115052A1 (en)2018-04-182020-11-25Hoffmann La Roche MULTI-SPECIFIC ANTIBODIES AND THE USE OF THEM
KR20210003814A (en)2018-04-182021-01-12젠코어 인코포레이티드 TIM-3 targeting heterodimer fusion protein containing IL-15/IL-15Rα Fc-fusion protein and TIM-3 antigen binding domain
SG11202010601VA (en)2018-05-032020-11-27Genmab BvAntibody variant combinations and uses thereof
GB201808927D0 (en)2018-05-312018-07-18Institute Of Cancer Res Royal Cancer HospitalMaterials and methods for monitoring the development of resistance of cancers to treatment
TWI848953B (en)2018-06-092024-07-21德商百靈佳殷格翰國際股份有限公司Multi-specific binding proteins for cancer treatment
WO2019241758A1 (en)2018-06-152019-12-19Alpine Immune Sciences, Inc.Pd-1 variant immunomodulatory proteins and uses thereof
EP3812399A4 (en)2018-06-202022-03-23Chugai Seiyaku Kabushiki KaishaMethod for activating immune response of target cell and composition therefor
EP3810194A1 (en)2018-06-222021-04-28Genmab Holding B.V.Anti-cd37 antibodies and anti-cd20 antibodies, compositions and methods of use thereof
CN112584851B (en)2018-06-222025-09-05科优基因公司 Novel interleukin-15 (IL-15) fusion protein and its use
EP3820890A1 (en)2018-07-132021-05-19Genmab A/STrogocytosis-mediated therapy using cd38 antibodies
CA3106146A1 (en)2018-07-132020-01-16Genmab A/SVariants of cd38 antibody and uses thereof
WO2020023553A1 (en)2018-07-242020-01-30Inhibrx, Inc.Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
WO2020023702A1 (en)2018-07-252020-01-30AskGene Pharma, Inc.Novel il-21 prodrugs and methods of use thereof
AU2019313550B2 (en)*2018-08-012024-02-08Novo Nordisk A/SImproved procoagulant antibodies
US11220554B2 (en)2018-09-072022-01-11Novo Nordisk A/SProcoagulant antibodies
MX2021001453A (en)2018-08-082021-04-12Genentech IncUse of tryptophan derivatives and l-methionine for protein formulation.
GB201814281D0 (en)2018-09-032018-10-17Femtogenix LtdCytotoxic agents
MX2021002573A (en)*2018-09-102021-05-12Genentech IncSystems and methods for affinity capillary electrophoresis.
US20220177587A1 (en)2018-09-192022-06-09Alpine Immune Sciences, Inc.Methods and uses of variant cd80 fusion proteins and related constructs
MA53822A (en)2018-10-032021-08-11Xencor Inc IL-12 HETERODIMER FC FUSION PROTEINS
BR112021006055A2 (en)2018-10-042021-07-20Genmab Holding B.V. pharmaceutical composition, use of the pharmaceutical composition, and, methods for inducing cell death or for inhibiting the growth and/or proliferation of a tumor cell and for treating an individual.
TW202028245A (en)2018-10-112020-08-01美商英伊布里克斯公司Dll3 single domain antibodies and therapeutic compositions thereof
CA3115082A1 (en)2018-10-112020-04-16Inhibrx, Inc.B7h3 single domain antibodies and therapeutic compositions thereof
CN113518647A (en)2018-10-112021-10-19印希比股份有限公司 5T4 single domain antibody and therapeutic composition thereof
AU2019356573A1 (en)2018-10-112021-05-27Inhibrx Biosciences, Inc.PD-1 single domain antibodies and therapeutic compositions thereof
JP7708662B2 (en)2018-10-242025-07-15エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Conjugated chemical degraders and methods of use
CN119033685A (en)2018-10-292024-11-29豪夫迈·罗氏有限公司Antibody formulations
WO2020089437A1 (en)2018-10-312020-05-07Engmab SàrlCombination therapy
SG11202104300PA (en)2018-11-062021-05-28Genmab AsAntibody formulation
JP7713886B2 (en)2018-11-302025-07-28アルパイン イミューン サイエンシズ インコーポレイテッド CD86 variant immunomodulatory proteins and uses thereof
JP2022513708A (en)2018-12-052022-02-09モルフォシス・アーゲー Multispecific antigen-binding molecule
CN113227119A (en)2018-12-102021-08-06基因泰克公司Photocrosslinked peptides for site-specific conjugation to Fc-containing proteins
TWI874341B (en)2018-12-182025-03-01美商健生生物科技公司Methods of producing heterodimeric antibodies
GB201820687D0 (en)2018-12-192019-01-30Kymab LtdAntagonists
KR20240155361A (en)2018-12-212024-10-28에프. 호프만-라 로슈 아게Antibodies binding to cd3
ES2901683T3 (en)2018-12-212022-03-23Kymab Ltd FIXAXFX bispecific antibody with common light chain
EP3902560A1 (en)2018-12-282021-11-03F. Hoffmann-La Roche AGA peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response
BR112021012569A2 (en)2018-12-282021-09-14Kyowa Kirin Co., Ltd. B-SPECIFIC TFR-BINDING ANTIBODY
CN114249818A (en)2018-12-312022-03-29美勒斯公司 truncated multivalent multivariate
CN113597319A (en)2019-01-042021-11-02分解治疗有限责任公司Treatment of xerosis with nuclease fusion proteins
GB201901197D0 (en)2019-01-292019-03-20Femtogenix LtdG-A Crosslinking cytotoxic agents
CN114173875B (en)2019-03-012025-04-15Xencor股份有限公司 Heterodimeric antibodies that bind ENPP3 and CD3
JP7249432B2 (en)2019-03-292023-03-30エフ． ホフマン－ラ ロシュ アーゲー SPR-based binding assays for functional analysis of multivalent molecules
EP3947440A1 (en)2019-03-292022-02-09F. Hoffmann-La Roche AGMethod for generating avid-binding multispecific antibodies
PH12021552538A1 (en)2019-04-052022-07-04Teneobio IncHeavy chain antibodies binding to psma
BR112021020447A2 (en)2019-04-172022-05-17Alpine Immune Sciences Inc Methods and uses of variant icos ligand fusion proteins (icosl)
MA55705A (en)2019-04-172022-02-23Novo Nordisk As BISPECIFIC ANTIBODIES
TW202106715A (en)2019-04-252021-02-16瑞士商赫孚孟拉羅股份公司Therapeutic multispecific polypeptides activated by polypeptide chain exchange
AU2020261250A1 (en)2019-04-252021-10-14F. Hoffmann-La Roche AgGeneration of antibody-derived polypeptides by polypeptide chain exchange
CN113767114A (en)2019-04-252021-12-07豪夫迈·罗氏有限公司 Activatable Therapeutic Multispecific Polypeptides with Extended Half-Life
US20220315661A1 (en)2019-05-092022-10-06Genmab B.V.Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer
CN113811770B (en)2019-05-132024-06-28豪夫迈·罗氏有限公司 Suppression of interference in pharmacokinetic immunoassays
EP3970743A4 (en)2019-05-152023-02-15Kyowa Kirin Co., Ltd.Bispecific antibody binding to cd40 and fap
EP3971293A4 (en)2019-05-152023-02-08Kyowa Kirin Co., Ltd. BISPECIFIC ANTIBODIES CAPABLE OF BINDING TO CD40 AND GPC3
CN113905757A (en)2019-06-052022-01-07中外制药株式会社 Antibody cleavage site binding molecule
AU2020291012B2 (en)2019-06-122025-09-25AskGene Pharma, Inc.Novel IL-15 prodrugs and methods of use thereof
EA202290054A1 (en)2019-06-142022-03-25Тенеобио, Инк. POLYSPECIFIC ANTIBODIES CONTAINING ONLY HEAVY CHAINS THAT BIND TO CD22 AND CD3
BR112021025425A2 (en)2019-06-192022-02-01Hoffmann La Roche Method for producing a recombinant mammalian cell and use of cre recombinase mRNA
HRP20250475T1 (en)2019-06-262025-06-06F. Hoffmann - La Roche AgMammalian cell lines with sirt-1 gene knockout
EP3994169A1 (en)2019-07-022022-05-11F. Hoffmann-La Roche AGImmunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody
TW202116805A (en)2019-07-102021-05-01日商中外製藥股份有限公司Claudin-6 binding molecules and uses thereof
AR119382A1 (en)2019-07-122021-12-15Hoffmann La Roche PRE-TARGETING ANTIBODIES AND METHODS OF USE
AR119393A1 (en)2019-07-152021-12-15Hoffmann La Roche ANTIBODIES THAT BIND NKG2D
JP7685985B2 (en)2019-07-162025-05-30サノフイ Neutralizing anti-amyloid beta antibodies for the treatment of Alzheimer's disease
BR112022001460A2 (en)2019-07-312022-03-22Hoffmann La Roche Bispecific antigen-binding molecules, one or more isolated polynucleotides, host cell, method for producing a bispecific antigen-binding molecule and for treating a disease in an individual, pharmaceutical composition, use of the bispecific antigen-binding molecule and invention
JP2022543551A (en)2019-07-312022-10-13エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Antibody that binds to GPRC5D
EP4013775A1 (en)2019-08-122022-06-22Askgene Pharma, Inc.Il-2 fusion proteins that preferentially bind il-2ralpha
CN115605504A (en)2019-08-212023-01-13奥美药业有限公司（Us）Novel IL-21 prodrugs and methods of use thereof
US12312414B2 (en)2019-09-182025-05-27Genentech, Inc.Anti-KLK7 antibodies, anti-KLK5 antibodies, multispecific anti-KLK5/KLK7 antibodies, and methods of use
AU2020355253A1 (en)*2019-09-272022-03-24Agenus Inc.Heterodimeric proteins
AU2020353235A1 (en)2019-09-282022-03-31AskGene Pharma, Inc.Cytokine prodrugs and dual-prodrugs
TWI770619B (en)2019-09-292022-07-11大陸商北京加科思新藥研發有限公司Binding molecules specific for lif and uses thereof
US20220411529A1 (en)2019-11-062022-12-29Genmab B.V.Antibody variant combinations and uses thereof
IL292899A (en)2019-11-152022-07-01Hoffmann La Roche Prevention of visible particle formation in aqueous protein solutions
WO2021119505A1 (en)2019-12-132021-06-17Genentech, Inc.Anti-ly6g6d antibodies and methods of use
WO2021122875A1 (en)2019-12-182021-06-24F. Hoffmann-La Roche AgAntibodies binding to hla-a2/mage-a4
BR112022012010A2 (en)2019-12-182022-08-30Hoffmann La Roche ANTIBODIES, ISOLATED NUCLEIC ACID, HOST CELL, PHARMACEUTICAL FORMULATION, USE OF THE ANTIBODY, METHOD OF PRODUCTION OF AN ANTIBODY, METHOD OF TREATMENT OF AN INDIVIDUAL THAT HAS CANCER, AND METHOD OF TREATMENT OF AN INDIVIDUAL THAT HAS AN INFLAMMATORY OR AUTOIMMUNE DISEASE
GB201919061D0 (en)2019-12-202020-02-05Ucb Biopharma SprlMulti-specific antibody
GB201919062D0 (en)2019-12-202020-02-05Ucb Biopharma SprlAntibody
MX2022007746A (en)2019-12-232022-10-07Genentech Inc APOLIPOPROTEIN L1 SPECIFIC ANTIBODIES AND METHODS OF USE.
CA3162444C (en)2019-12-272024-04-30Hitoshi KATADAAnti-ctla-4 antibody and use thereof
EP4085251B1 (en)2020-01-022024-07-31F. Hoffmann-La Roche AGMethod for determining the amount of a therapeutic antibody in the brain
CN114901679B (en)2020-01-112025-03-11奥美药业有限公司 New masked cytokines and their applications
MX2022008442A (en)2020-01-152022-08-02Hoffmann La RocheMethods to decrease impurities from recombinant protein manufacturing processes.
IL294453A (en)2020-01-162022-09-01Genmab As Formulations of cd38 antibodies and uses thereof
IL294879A (en)2020-01-292022-09-01Inhibrx Inc Monodomain antibodies of cd28 and their multivalent and multispecific constructs
GB202001447D0 (en)2020-02-032020-03-18Ucb Biopharma SprlAntibodies
WO2021155916A1 (en)2020-02-042021-08-12BioNTech SETreatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
WO2021173844A1 (en)2020-02-262021-09-02Biograph 55, Inc.C19 c38 bispecific antibodies
EP4118114A1 (en)2020-03-132023-01-18Genentech, Inc.Anti-interleukin-33 antibodies and uses thereof
TW202200624A (en)2020-03-182022-01-01丹麥商珍美寶股份有限公司Antibodies
EP4127153A2 (en)2020-03-262023-02-08Genentech, Inc.Modified mammalian cells having reduced host cell proteins
IL296514A (en)2020-03-302022-11-01Univ Mie Bispecific antibody
IL296802A (en)2020-03-312022-11-01Chugai Pharmaceutical Co Ltd A method for the production of multispecific antigen binding molecules
BR112022020629A2 (en)2020-04-152022-11-29Hoffmann La Roche INTERLEUKIN-7 (IL-7) POLYPEPTIDE, IMMUNOCONJUGATE, ONE OR MORE POLYNUCLEOTIDES ISOLATED, HOST CELL, METHODS FOR PRODUCING AN IL-7 POLYPEPTIDE MUTANT OR AN IMMUNOCONJUGATE, FOR TREAT A DISEASE, AND FOR STIMULATING THE IMMUNE SYSTEM, IL-7 POLYPEPTIDE OR IMMUNOCONJUGATE 7 MUTANT, PHARMACEUTICAL COMPOSITION, USE OF THE IL-7 MUTANT POLYPEPTIDE AND INVENTION
KR20230005172A (en)2020-04-242023-01-09에프. 호프만-라 로슈 아게 Modulation of enzymes and pathways using sulfhydryl compounds and their derivatives
MX2022013453A (en)2020-04-292022-11-16Teneobio Inc MULTI-SPECIFIC HEAVY CHAIN ANTIBODIES WITH MODIFIED HEAVY CHAIN CONSTANT REGIONS.
AU2021263408A1 (en)2020-04-302022-10-27Bristol-Myers Squibb CompanyMethods of treating cytokine-related adverse events
IL297980A (en)2020-05-082023-01-01Alpine Immune Sciences IncApril and baff inhibitory immunomodulatory proteins and methods of use thereof
US20230227570A1 (en)2020-05-082023-07-20Genmab A/SBispecific antibodies against cd3 and cd20
CR20220576A (en)2020-05-112022-12-07Hoffmann La Roche COMMON THERAPY WITH MODIFIED PBMC AND AN IMMUNOCONJUGATE
WO2021231976A1 (en)2020-05-142021-11-18Xencor, Inc.Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
EP4149421A1 (en)2020-05-152023-03-22F. Hoffmann-La Roche AGPrevention of visible particle formation in parenteral protein solutions
CN115605185A (en)2020-05-192023-01-13豪夫迈·罗氏有限公司（Ch）Use of a chelating agent to prevent the formation of visible particles in parenteral protein solutions
EP4159859A4 (en)2020-05-272024-07-10Arialys Therapeutics, Inc. ANTI-HUMAN NR1 ANTIBODY DERIVATIVE
JP2023527918A (en)2020-06-082023-06-30エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Anti-HBV antibody and method of use
WO2021255146A1 (en)2020-06-192021-12-23F. Hoffmann-La Roche AgAntibodies binding to cd3 and cea
PH12022500027A1 (en)2020-06-192024-03-25Hoffmann La RocheAntibodies binding to cd3
MX2022015203A (en)2020-06-192023-01-05Hoffmann La RocheImmune activating fc domain binding molecules.
BR112022025809A2 (en)2020-06-192023-01-10Hoffmann La Roche ANTIBODIES, ISOLATED POLYNUCLEOTIDE, HOST CELL, METHOD FOR PRODUCING AN ANTIBODY, USE OF THE ANTIBODY, METHOD FOR TREATING A DISEASE AND INVENTION
TWI811703B (en)2020-06-192023-08-11瑞士商赫孚孟拉羅股份公司Antibodies binding to cd3 and cd19
EP4172192A1 (en)2020-06-242023-05-03Genentech, Inc.Apoptosis resistant cell lines
EP4171614A1 (en)2020-06-292023-05-03Resolve Therapeutics, LLCTreatment of sjogren's syndrome with nuclease fusion proteins
WO2022008468A1 (en)2020-07-072022-01-13F. Hoffmann-La Roche AgAlternative surfactants as stabilizers for therapeutic protein formulations
MX2023000339A (en)2020-07-102023-02-09Hoffmann La RocheAntibodies which bind to cancer cells and target radionuclides to said cells.
TW202216780A (en)2020-07-172022-05-01美商建南德克公司Anti-notch2 antibodies and methods of use
CN116249556A (en)2020-07-212023-06-09基因泰克公司 Antibody-conjugated chemical inducers for degrading BRM and methods thereof
WO2022018294A1 (en)2020-07-232022-01-27Genmab B.V.A combination of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma
GB2597532A (en)2020-07-282022-02-02Femtogenix LtdCytotoxic compounds
IL300225A (en)2020-07-312023-03-01Chugai Pharmaceutical Co LtdPharmaceutical composition including cell expressing chimeric receptor
JP2023537470A (en)*2020-08-032023-09-01ヤンセン バイオテツク，インコーポレーテツド Materials and methods for multidirectional biotransport in viral therapy
CN116194477A (en)2020-08-062023-05-30生物技术欧洲股份公司Binding agents to coronavirus S proteins
JP2023538891A (en)2020-08-192023-09-12ゼンコア インコーポレイテッド Anti-CD28 composition
KR20230056766A (en)2020-08-282023-04-27제넨테크, 인크. CRISPR/Cas9 multiple knockout of host cell proteins
US20230416371A1 (en)2020-08-282023-12-28Chugai Seiyaku Kabushiki KaishaHeterodimer fc polypeptide
CA3190349A1 (en)2020-09-102022-03-17Brian ElliottBispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia
US20230312759A1 (en)2020-09-102023-10-05Genmab A/SBispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
MX2023002542A (en)2020-09-102023-03-15Genmab AsBispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma.
IL301086A (en)2020-09-102023-05-01Genmab As Bispecific antibody against CD3 and CD20 in combination therapy for the treatment of follicular lymphoma
AU2021341509A1 (en)2020-09-102023-04-13Genmab A/SBispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma
BR112023004321A2 (en)2020-09-102023-04-04Genmab As METHOD FOR TREATMENT OF DIFFUSED GRAND B-CELL LYMPHOMA IN A HUMAN SUBJECT
EP4214244A1 (en)2020-09-212023-07-26Genentech, Inc.Purification of multispecific antibodies
AU2021347580A1 (en)2020-09-242023-04-06F. Hoffmann-La Roche AgMammalian cell lines with gene knockout
US20230365714A1 (en)2020-10-022023-11-16Genmab A/SAntibodies capable of binding to ror2 and bispecific antibodies binding to ror2 and cd3
TW202446417A (en)2020-10-052024-12-01美商建南德克公司Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
AR123855A1 (en)2020-10-202023-01-18Genentech Inc PEG-CONJUGATED ANTI-MERTK ANTIBODIES AND METHODS OF USE
US12351643B2 (en)2020-11-042025-07-08Genentech, Inc.Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
US20240010748A1 (en)2020-11-102024-01-11Shanghai Qilu Pharmaceutical Research And Development Centre Ltd.Bispecific antibody for claudin 18a2 and cd3 and application of bispecific antibody
IL302740A (en)2020-11-162023-07-01Hoffmann La Roche High mannose glycoforms
KR20230108288A (en)2020-11-162023-07-18아스텔라스세이야쿠 가부시키가이샤 Anti-TSPAN8-anti-CD3 bispecific antibody and anti-TSPAN8 antibody
EP4255926A1 (en)2020-12-072023-10-11UCB Biopharma SRLMulti-specific antibodies and antibody combinations
US20230416357A1 (en)2020-12-072023-12-28UCB Biopharma SRLAntibodies against interleukin-22
IL303656A (en)2020-12-172023-08-01Hoffmann La Roche ANTI-HLA-G antibodies and their use
WO2022129313A1 (en)2020-12-182022-06-23F. Hoffmann-La Roche AgPrecursor proteins and kit for targeted therapy
CN116670282A (en)2020-12-222023-08-29豪夫迈·罗氏有限公司XBP 1-targeting oligonucleotides
EP4274658A1 (en)2021-01-062023-11-15F. Hoffmann-La Roche AGCombination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody
WO2022148853A1 (en)2021-01-112022-07-14F. Hoffmann-La Roche AgImmunoconjugates
JP2024504931A (en)2021-01-122024-02-02エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Split antibodies that bind to cancer cells and target radionuclides to said cells
EP4277668A1 (en)2021-01-132023-11-22F. Hoffmann-La Roche AGCombination therapy
WO2022155541A1 (en)2021-01-142022-07-21AskGene Pharma, Inc.Interferon prodrugs and methods of making and using the same
US20240076331A1 (en)2021-02-012024-03-07AskGene Pharma, Inc.Chimeric Molecules Comprising an IL-10 or TGF-Beta Agonist Polypeptide
WO2022169872A1 (en)2021-02-032022-08-11Genentech, Inc.Multispecific binding protein degrader platform and methods of use
WO2022178103A1 (en)2021-02-172022-08-25AskGene Pharma, Inc.Il-2 receptor beta subunit mutants
JP2024512240A (en)2021-02-182024-03-19エフ． ホフマン－ラ ロシュ アーゲー Methods for elucidating complex multistep antibody interactions
WO2022192403A1 (en)2021-03-092022-09-15Xencor, Inc.Heterodimeric antibodies that bind cd3 and cldn6
US11859012B2 (en)2021-03-102024-01-02Xencor, Inc.Heterodimeric antibodies that bind CD3 and GPC3
IL305636A (en)2021-03-122023-11-01Genmab AsNon-activating antibody variants
JP2024512377A (en)2021-03-122024-03-19ジェネンテック， インコーポレイテッド Anti-KLK7 antibodies, anti-KLK5 antibodies, multispecific anti-KLK5/KLK7 antibodies, and methods of use
WO2022197877A1 (en)2021-03-192022-09-22Genentech, Inc.Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
KR20230165245A (en)2021-03-312023-12-05에프. 호프만-라 로슈 아게 Purification of antibodies by mixed mode chromatography
JP2024514077A (en)2021-03-312024-03-28江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 Truncated TACI polypeptides and fusion proteins thereof and uses
JP2024513474A (en)2021-04-092024-03-25エフ． ホフマン－ラ ロシュ アーゲー Method for selecting cell clones expressing heterologous polypeptides
US20240190993A1 (en)2021-04-142024-06-13INSERM (Institut National de la Santé et de la Recherche Médicale)New method to improve the anti-tumoral activity of macrophages
US20240228659A1 (en)2021-04-142024-07-11INSERM (Institut National de la Santé et de la Recherche Médicale)New method to improve nk cells cytotoxicity
KR20230173164A (en)2021-04-192023-12-26제넨테크, 인크. modified mammalian cells
WO2022228706A1 (en)2021-04-302022-11-03F. Hoffmann-La Roche AgDosing for treatment with anti-cd20/anti-cd3 bispecific antibody
CN117321078A (en)2021-04-302023-12-29豪夫迈·罗氏有限公司Administration for combination therapy with anti-CD 20/anti-CD 3 bispecific antibody and anti-CD 79B antibody drug conjugates
CN117642428A (en)2021-05-032024-03-01Ucb生物制药有限责任公司 Antibody
CA3214582A1 (en)2021-05-072022-11-10Martin SAHLINPharmaceutical compositions comprising bispecific antibodies binding to b7h4 and cd3
CA3216795A1 (en)2021-05-072022-11-10Alpine Immune Sciences, Inc.Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
WO2022237856A1 (en)2021-05-122022-11-17江苏恒瑞医药股份有限公司Antigen binding molecule specifically binding to rankl and ngf, and medical use thereof
EP4339213A4 (en)2021-05-142025-01-15Jiangsu Hengrui Pharmaceuticals Co., Ltd. ANTIGEN-BINDING MOLECULES
WO2022241235A1 (en)2021-05-142022-11-17Genentech, Inc.Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
EP4341385A1 (en)2021-05-212024-03-27Genentech, Inc.Modified cells for the production of a recombinant product of interest
WO2022266223A1 (en)2021-06-162022-12-22Alector LlcBispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
US20240279358A1 (en)2021-06-162024-08-22Alector LlcMonovalent anti-mertk antibodies and methods of use thereof
CA3221735A1 (en)2021-06-182022-12-22F. Hoffmann-La Roche AgBispecific anti-ccl2 antibodies
EP4359435A1 (en)2021-06-212024-05-01Genmab A/SCombination dosage regime of cd137 and pd-l1 binding agents
TW202306999A (en)2021-06-242023-02-16美商艾瑞斯卡公司Antibodies against egfr and their uses
PE20242297A1 (en)2021-06-252024-12-11Chugai Pharmaceutical Co Ltd ANTI-CTLA-4 ANTIBODY
CA3220353A1 (en)2021-06-252022-12-29Chugai Seiyaku Kabushiki KaishaUse of anti-ctla-4 antibody
MX2023015416A (en)2021-07-022024-04-30Genentech IncMethods and compositions for treating cancer.
JP2024529339A (en)2021-07-132024-08-06ジェネンテック， インコーポレイテッド Multivariate model for predicting cytokine release syndrome
TW202317635A (en)2021-07-142023-05-01大陸商江蘇恆瑞醫藥股份有限公司Antigen-binding molecule that specifically binds to hgfr and egfr and the pharmaceutical use thereof
WO2023288241A1 (en)2021-07-142023-01-19Genentech, Inc.Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
KR20240036570A (en)2021-07-222024-03-20에프. 호프만-라 로슈 아게 Heterodimeric Fc domain antibodies
CA3227537A1 (en)2021-07-272023-02-02Morphosys AgCombinations of antigen binding molecules
IL309120A (en)2021-07-282024-02-01Hoffmann La RocheMethods and compositions for treating cancer
EP4380980A1 (en)2021-08-032024-06-12F. Hoffmann-La Roche AGBispecific antibodies and methods of use
GB202111905D0 (en)2021-08-192021-10-06UCB Biopharma SRLAntibodies
MX2024002781A (en)2021-09-062024-04-16Genmab As ANTIBODIES CAPABLE OF BIDING CLUSTER OF DIFFERENTIATION 27 (CD27), VARIANTS THEREOF AND THEIR USES.
IL311337A (en)2021-09-082024-05-01Joint Stock Company «Biocad»Bispecific antibody comprising a heterodimer based on mhc proteins
KR20240067092A (en)2021-09-232024-05-16지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Anti-KLB antibodies and uses
JPWO2023053282A1 (en)2021-09-292023-04-06
TW202323304A (en)2021-09-302023-06-16大陸商江蘇恆瑞醫藥股份有限公司Anti-il23 antibody fusion protein and uses thereof
UY39967A (en)2021-10-062023-05-15Immatics Biotechnologies Gmbh Indications for anti-PRAME binders
AU2022361184A1 (en)2021-10-082024-05-09Chugai Seiyaku Kabushiki KaishaMethod for preparing prefilled syringe formulation
KR20240082397A (en)2021-10-082024-06-10젠맵 에이/에스 Antibodies that bind to CD30 and CD3
JP2024537096A (en)2021-10-142024-10-10エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Alternative PD1-IL7v immunoconjugates for the treatment of cancer
AU2022362681A1 (en)2021-10-142024-04-04F. Hoffmann-La Roche AgNew interleukin-7 immunoconjugates
EP4448108A1 (en)2021-11-082024-10-23Immatics Biotechnologies GmbHAdoptive cell therapy combination treatment and compositions thereof
EP4437344A1 (en)2021-11-252024-10-02F. Hoffmann-La Roche AGQuantification of low amounts of antibody sideproducts
AR127887A1 (en)2021-12-102024-03-06Hoffmann La Roche ANTIBODIES THAT BIND CD3 AND PLAP
WO2023114658A1 (en)2021-12-132023-06-22Kenjockety Biotechnology, Inc.Anti-abcb1 antibodies
EP4416301B1 (en)2021-12-212025-06-11F. Hoffmann-La Roche AGMethod for the determination of hydrolytic activity
US20230322958A1 (en)2022-01-192023-10-12Genentech, Inc.Anti-Notch2 Antibodies and Conjugates and Methods of Use
US20230303693A1 (en)2022-01-282023-09-28Genmab A/SBispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
US20230241211A1 (en)2022-01-282023-08-03Genmab A/SBispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
TW202337902A (en)2022-02-072023-10-01大陸商江蘇恆瑞醫藥股份有限公司Antigen-binding molecules that specifically bind psma and cd3 and the pharmaceutical use thereof
EP4477673A4 (en)2022-02-112025-09-03Jiangsu Hengrui Pharmaceuticals Co Ltd IMMUNOCONJUGATE AND ITS USE
WO2023159220A1 (en)2022-02-182023-08-24Kenjockety Biotechnology, Inc.Anti-cd47 antibodies
EP4490173A1 (en)2022-03-072025-01-15Alpine Immune Sciences, Inc.Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
WO2023174238A1 (en)2022-03-142023-09-21江苏恒瑞医药股份有限公司Antigen-binding molecule specifically binding to gprc5d and cd3 and medical use thereof
WO2023174521A1 (en)2022-03-152023-09-21Genmab A/SBinding agents binding to epcam and cd137
IL315451A (en)2022-03-172024-11-01Astrazeneca AbMethods for purifying bispecific antibodies
IL314211A (en)2022-03-232024-09-01Genentech IncCombination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
WO2023191816A1 (en)2022-04-012023-10-05Genentech, Inc.Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
EP4508081A1 (en)2022-04-132025-02-19F. Hoffmann-La Roche AGPharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
WO2023198839A2 (en)2022-04-132023-10-19Genmab A/SBispecific antibodies against cd3 and cd20
JP2025513335A (en)2022-04-192025-04-24エフ． ホフマン－ラ ロシュ アーゲー Improved Producer Cells
PE20250005A1 (en)2022-05-022025-01-07Novo Nordisk As Novel anti-ANGPTL3 antibodies suitable for high concentration compositions and subcutaneous administration
IL316738A (en)2022-05-112024-12-01Genentech IncDosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
CN119365215A (en)2022-05-122025-01-24健玛保Binding agents capable of binding CD27 in combination therapies
JPWO2023219121A1 (en)2022-05-122023-11-16
EP4522657A1 (en)2022-05-122025-03-19Genmab A/SBinding agents capable of binding to cd27 in combination therapy
IL316630A (en)2022-05-132024-12-01BioNTech SERna compositions targeting hiv
JP2025517572A (en)2022-06-032025-06-05エフ． ホフマン－ラ ロシュ アーゲー Improved Producer Cells
KR20250027562A (en)2022-06-232025-02-26지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Antigen binding molecule specifically binding to DLL3 and CD3 and medicinal uses thereof
AU2023305619A1 (en)2022-07-132025-01-23F. Hoffmann-La Roche AgDosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
EP4558524A1 (en)2022-07-192025-05-28Genentech, Inc.Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
CN119604525A (en)2022-07-222025-03-11信达生物制药(苏州)有限公司 Mutants that promote homologous pairing of heavy and light chains of multispecific antibodies
TW202417504A (en)2022-07-222024-05-01美商建南德克公司Anti-steap1 antigen-binding molecules and uses thereof
WO2024026471A1 (en)2022-07-292024-02-01Alector LlcCd98hc antigen-binding domains and uses therefor
EP4562044A2 (en)2022-07-292025-06-04Alector LLCTransferrin receptor antigen-binding domains and uses therefor
TW202413437A (en)2022-08-052024-04-01大陸商江蘇恆瑞醫藥股份有限公司Antigen binding molecules specifically binding to gucy2c and cd3 and their medical uses
KR20250099778A (en)2022-10-042025-07-02알파인 이뮨 사이언시즈, 인코포레이티드 Mutated TACI-FC fusion proteins for use in the treatment of autoantibody-mediated diseases
TW202421664A (en)2022-10-072024-06-01美商建南德克公司Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies
TW202423970A (en)2022-10-102024-06-16瑞士商赫孚孟拉羅股份公司Combination therapy of a gprc5d tcb and cd38 antibodies
TW202423969A (en)2022-10-102024-06-16瑞士商赫孚孟拉羅股份公司Combination therapy of a gprc5d tcb and proteasome inhibitors
TW202430211A (en)2022-10-102024-08-01瑞士商赫孚孟拉羅股份公司Combination therapy of a gprc5d tcb and imids
WO2024079069A1 (en)2022-10-122024-04-18F. Hoffmann-La Roche AgMethod for classifying cells
WO2024081918A1 (en)2022-10-142024-04-18Talem Therapeutics LlcAnti-trkb/cd3 antibodies and uses thereof
EP4608861A1 (en)2022-10-242025-09-03F. Hoffmann-La Roche AGPredicting response to il-6 antagonists
WO2024091991A1 (en)2022-10-252024-05-02Genentech, Inc.Therapeutic and diagnostic methods for multiple myeloma
TW202432177A (en)2022-10-312024-08-16丹麥商珍美寶股份有限公司Cd38 antibodies and uses thereof
EP4613767A1 (en)2022-11-012025-09-10Shanghai Qilu Pharmaceutical Research and Development Centre Ltd.Bispecific antibody for glypican-3 and use thereof
CN120077073A (en)2022-11-022025-05-30健玛保Bispecific antibodies against CD3 and CD20 for the treatment of rischet syndrome
WO2024100170A1 (en)2022-11-112024-05-16F. Hoffmann-La Roche AgAntibodies binding to hla-a*02/foxp3
WO2024102948A1 (en)2022-11-112024-05-16Celgene CorporationFc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
CN120187749A (en)2022-11-152025-06-20豪夫迈·罗氏有限公司 Recombinant binding protein with activatable effector domain
EP4619428A1 (en)2022-11-152025-09-24F. Hoffmann-La Roche AGAntigen binding molecules
CN120225684A (en)2022-11-232025-06-27豪夫迈·罗氏有限公司Methods for increasing expression of recombinant proteins
CN120187458A (en)2022-11-242025-06-20广州百济神州生物制药有限公司 Anti-CEA antibody drug conjugates and methods of use
AR131163A1 (en)2022-11-252025-02-19Chugai Pharmaceutical Co Ltd METHODS FOR PRODUCING PROTEINS
TW202421667A (en)2022-11-292024-06-01大陸商江蘇恆瑞醫藥股份有限公司Cldn18.2/4-1bb binding protein and the pharmaceutical use thereof
WO2024119193A2 (en)2022-12-022024-06-06AskGene Pharma, Inc.Mutant il-2 polypeptides and il-2 prodrugs
EP4631974A1 (en)2022-12-082025-10-15Nanjing Vazyme Biotech Co., Ltd.Antibody specifically binding to rsv
WO2024129594A1 (en)2022-12-122024-06-20Genentech, Inc.Optimizing polypeptide sialic acid content
US12195546B2 (en)2022-12-192025-01-14SanofiCD28/OX40 bispecific antibodies
WO2024141955A1 (en)2022-12-282024-07-04BioNTech SERna compositions targeting hiv
TW202432607A (en)2023-01-182024-08-16美商建南德克公司Multispecific antibodies and uses thereof
AR131637A1 (en)2023-01-192025-04-16Beigene Ltd ANTI-cMET ANTIBODIES AND METHODS OF USE
KR20250135861A (en)2023-01-202025-09-15에프. 호프만-라 로슈 아게 Combination therapy with recombinant Fc domain-IL2 variant polypeptide and membrane-anchored antigen-binding polypeptide
CN120569410A (en)2023-01-252025-08-29豪夫迈·罗氏有限公司Antibodies that bind to CSF1R and CD3
WO2024163494A1 (en)2023-01-312024-08-08F. Hoffmann-La Roche AgMethods and compositions for treating non-small cell lung cancer and triple-negative breast cancer
WO2024163009A1 (en)2023-01-312024-08-08Genentech, Inc.Methods and compositions for treating urothelial bladder cancer
AR132040A1 (en)2023-03-032025-05-21Beigene Switzerland Gmbh MUC1 AND CD16A ANTIBODIES AND METHODS OF USE
AR132043A1 (en)2023-03-032025-05-21Beigene Switzerland Gmbh MUC1 ANTIBODIES AND METHODS OF USE
TW202436344A (en)2023-03-032024-09-16瑞士商百濟神州瑞士有限責任公司Cd16a antibodies and methods of use
WO2024184810A1 (en)2023-03-062024-09-12Beigene Switzerland GmbhAnti-cldn6 and anti-cd3 multispecific antibodies and methods of use
WO2024184287A1 (en)2023-03-062024-09-12F. Hoffmann-La Roche AgCombination therapy of an anti-egfrviii/anti-cd3 antibody and an tumor-targeted 4-1bb agonist
TW202436345A (en)2023-03-062024-09-16瑞士商百濟神州瑞士有限責任公司Anti-cd3 multispecific antibodies and methods of use
AR132064A1 (en)2023-03-062025-05-21Beigene Switzerland Gmbh ANTI-CLDN6 ANTIBODIES AND METHODS OF USE
WO2024191785A1 (en)2023-03-102024-09-19Genentech, Inc.Fusions with proteases and uses thereof
WO2024188965A1 (en)2023-03-132024-09-19F. Hoffmann-La Roche AgCombination therapy employing a pd1-lag3 bispecific antibody and an hla-g t cell bispecific antibody
GB202303784D0 (en)2023-03-152023-04-26Institute Of Cancer Res Royal Cancer HospitalCancer treatment
AU2024239150A1 (en)2023-03-212025-10-02Biograph 55, Inc.Cd19/cd38 multispecific antibodies
US20240327522A1 (en)2023-03-312024-10-03Genentech, Inc.Anti-alpha v beta 8 integrin antibodies and methods of use
WO2024208777A1 (en)2023-04-032024-10-10F. Hoffmann-La Roche AgAll-in-one agonistic antibodies
WO2024208776A1 (en)2023-04-032024-10-10F. Hoffmann-La Roche AgAgonistic split antibodies
TW202506178A (en)2023-04-052025-02-16丹麥商珍美寶股份有限公司Pharmaceutical compositions comprising antibodies binding to cd30 and cd3
AU2024255174A1 (en)2023-04-132025-10-09Genmab A/SMethods of treating lymphoma with bispecific antibodies against cd3 and cd20
WO2024220546A2 (en)2023-04-172024-10-24Peak Bio, Inc.Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates
WO2024233341A1 (en)2023-05-052024-11-14Genentech, Inc.Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024231320A1 (en)2023-05-082024-11-14F. Hoffmann-La Roche AgTargeted interferon alpha fusion proteins and methods of use
WO2024235862A1 (en)2023-05-122024-11-21Genmab A/SAntibodies capable of binding to ox40, variants thereof and uses thereof
TW202509065A (en)2023-05-162025-03-01瑞士商赫孚孟拉羅股份公司Pd-1-regulated il-2 immunoconjugates and uses thereof
WO2024263761A1 (en)2023-06-222024-12-26Genentech, Inc.Antibodies and uses thereof
TW202504929A (en)2023-06-222025-02-01美商建南德克公司Methods and compositions for cancer treatment
WO2024263904A1 (en)2023-06-232024-12-26Genentech, Inc.Methods for treatment of liver cancer
WO2024263195A1 (en)2023-06-232024-12-26Genentech, Inc.Methods for treatment of liver cancer
US12351650B2 (en)2023-06-302025-07-08Genmab A/SAntibodies binding to fibroblast activation protein alpha and death receptor 4
WO2025021838A1 (en)2023-07-262025-01-30F. Hoffmann-La Roche AgAntibodies binding to cd3
AR133412A1 (en)2023-07-302025-09-24Janssen Biotech Inc Molecules that bind to mutant calreticulin and their uses
WO2025027579A2 (en)2023-08-032025-02-06BioNTech SERna compositions targeting hiv
WO2025027576A2 (en)2023-08-032025-02-06BioNTech SERna compositions targeting hiv
WO2025032069A1 (en)2023-08-092025-02-13F. Hoffmann-La Roche AgMono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025032071A1 (en)2023-08-092025-02-13F. Hoffmann-La Roche AgMono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025038362A1 (en)2023-08-112025-02-20Merck Sharp & Dohme LlcMonovalent interleukin 12 (il-12) heterodimeric fc proteins
WO2025038668A1 (en)2023-08-142025-02-20Voro Therapeutics, Inc.Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof
WO2025036892A1 (en)2023-08-142025-02-20Morphosys AgCycat halfbody molecules comprising sterically occluding moieties
WO2025042742A1 (en)2023-08-182025-02-27Bristol-Myers Squibb CompanyCompositions comprising antibodies that bind bcma and cd3 and methods of treatment
WO2025040567A1 (en)2023-08-182025-02-27F. Hoffmann-La Roche AgProtease activatable fc domain binding molecules
TW202525845A (en)2023-08-232025-07-01法商賽諾菲公司Ctla-4-based lysosomal degraders and uses thereof
WO2025059162A1 (en)2023-09-112025-03-20Dana-Farber Cancer Institute, Inc.Car-engager containing il-2 variants to enhance the functionality of car t cells
WO2025057088A1 (en)2023-09-112025-03-20BioNTech SERna compositions for delivery of incretin agents
WO2025056180A1 (en)2023-09-152025-03-20BioNTech SEMethods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
TW202517673A (en)2023-09-252025-05-01瑞士商赫孚孟拉羅股份公司Antibody that binds to c3bbb
WO2025082777A1 (en)2023-10-172025-04-24Morphosys AgDual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules
WO2025087681A1 (en)2023-10-262025-05-01Morphosys AgBispecific antibodies against cd3 and cd20
WO2025099632A1 (en)2023-11-082025-05-15SanofiCd25 based lysosomal degrader and uses thereof
WO2025106474A1 (en)2023-11-142025-05-22Genentech, Inc.Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies
WO2025114541A1 (en)2023-11-302025-06-05Genmab A/SAntibodies capable of binding to ox40 in combination therapy
WO2025113643A1 (en)2023-12-012025-06-05Gilead Sciences Inc.Anti-fap-light fusion protein and use thereof
WO2025125386A1 (en)2023-12-142025-06-19F. Hoffmann-La Roche AgAntibodies that bind to folr1 and methods of use
WO2025132503A1 (en)2023-12-202025-06-26F. Hoffmann-La Roche AgAntibodies binding to ceacam5
WO2025137086A1 (en)2023-12-202025-06-26Genentech, Inc.Reducing alpha-gal
WO2025133042A2 (en)2023-12-222025-06-26F. Hoffmann-La Roche AgActivatable fusion proteins and methods of use
WO2025147696A1 (en)2024-01-052025-07-10Resolve Therapeutics, LlcTreatment of symptoms associated with sars-cov viral infection or a prior sars-cov viral infection with nuclease agents
WO2025166045A1 (en)2024-01-312025-08-07Alector Llcβ-GLUCOCEREBROSIDASE ENZYMES, FUSION PROTEINS AND COMPLEXES COMPRISING THE SAME, AND METHODS OF USE THEREOF
WO2025166077A1 (en)2024-01-312025-08-07Alector LlcCompositions comprising progranulin and uses thereof
WO2025166042A1 (en)2024-01-312025-08-07Alector LlcCd98hc antigen-binding domains and uses therefor
WO2025166040A1 (en)2024-01-312025-08-07Alector LlcMulti-specific binding proteins that bind to gpnmb and a blood brain barrier target and methods of use thereof
WO2025168826A1 (en)2024-02-082025-08-14Hemab ApsMethods of treating coagulopathy
WO2025181189A1 (en)2024-03-012025-09-04F. Hoffmann-La Roche AgAntibodies binding to cd3
WO2025202147A1 (en)2024-03-272025-10-02F. Hoffmann-La Roche AgInterleukin-7 immunoconjugates

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4816567A (en)1983-04-081989-03-28Genentech, Inc.Recombinant immunoglobin preparations
NZ226414A (en)1987-10-021992-07-28Genentech IncCd4 peptide adhesion variants and their preparation and use
US5116964A (en)1989-02-231992-05-26Genentech, Inc.Hybrid immunoglobulins
DE3920358A1 (en)1989-06-221991-01-17Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
EP0563214A4 (en)*1990-12-041994-08-17Wistar InstBifunctional antibodies and method of preparing same
US6407213B1 (en)1991-06-142002-06-18Genentech, Inc.Method for making humanized antibodies
EP0604580A1 (en)1991-09-191994-07-06Genentech, Inc.EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
US6027725A (en)1991-11-252000-02-22Enzon, Inc.Multivalent antigen-binding proteins
US5932448A (en)1991-11-291999-08-03Protein Design Labs., Inc.Bispecific antibody heterodimers
US5731168A (en)1995-03-011998-03-24Genentech, Inc.Method for making heteromultimeric polypeptides
EP0827544B1 (en)1995-05-232004-08-18MorphoSys AGMultimeric proteins
US20020062010A1 (en)1997-05-022002-05-23Genentech, Inc.Method for making multispecific antibodies having heteromultimeric and common components
US7951917B1 (en)*1997-05-022011-05-31Genentech, Inc.Method for making multispecific antibodies having heteromultimeric and common components
WO2003054164A2 (en)2001-12-192003-07-03Immunex CorporationC-type lectin polypeptide, polynucleotide and methods of making and use thereof
CA2872136C (en)*2002-07-182017-06-20Merus B.V.Recombinant production of mixtures of antibodies

Also Published As

Publication numberPublication date
EP0979281B1 (en)2005-07-20
JP4213224B2 (en)2009-01-21
WO1998050431A3 (en)1999-01-14
US20070178552A1 (en)2007-08-02
AU751659B2 (en)2002-08-22
CA2288600A1 (en)1998-11-12
EP0979281A2 (en)2000-02-16
AU7270998A (en)1998-11-27
DE69830901D1 (en)2005-08-25
IL132560A0 (en)2001-03-19
US8642745B2 (en)2014-02-04
ATE299938T1 (en)2005-08-15
WO1998050431A2 (en)1998-11-12
US20140322756A1 (en)2014-10-30
ES2246069T3 (en)2006-02-01
CA2288600C (en)2010-06-01
US9409989B2 (en)2016-08-09
JP2001523971A (en)2001-11-27
DE69830901T2 (en)2006-05-24
JP4324231B2 (en)2009-09-02
JP2009039122A (en)2009-02-26

Similar Documents

PublicationPublication DateTitle
DK0979281T3 (en) Process for the preparation of multispecific antibodies with heteromultimers and common components
NO973982L (en) Process for the preparation of heteromultimeric polypeptides
PL374311A1 (en)Methods for purifying protein
WO2001070984A3 (en)Anti-tissue factor antibodies with enhanced anticoagulant potency
DK0458841T3 (en) Process for use and preparation of peptides
DE122009000068I1 (en) Process for the preparation of heterologous bispecific antibodies
IL130403A (en)Oil bodies and associated proteins as affinity matrices
AU1986588A (en)Growth hormone receptor
DK60586A (en) INHIBIN ISOLATED FROM OVARIE FOLLICLE LIQUID AND PROCEDURE FOR INHIBIN ISOLATION AND CLEANING
WO1998050433A3 (en)Human monoclonal antibodies to epidermal growth factor receptor
EP0267781A3 (en)Method for selecting hybridomas producing antibodies specific to the p-glycoprotein cell surface antigen and a cdna clone encoding the c-term
AU3066489A (en)Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore
DE3750342D1 (en) Human gamma interferon-specific receptor protein, antibodies against this protein, methods for producing this protein and antibody and compositions containing this protein and antibody.
DE69230146D1 (en) MONOCLONAL ANTIBODIES AGAINST PUTATIVE HCV-E2 / NS1 PROTEINS AND METHOD FOR THEIR USE
KR960704938A (en) Fas Antagonists and Uses Thereof
DK677688D0 (en) HUMAN SOMATOMETRICATED PROTEIN SUBSTANCES AND PROCEDURES FOR MANUFACTURING SUCH
WO2000023565A3 (en)Novel neuropilin/growth factor binding and uses thereof
WO1997011968A3 (en)A gene associated with liver neoplastic disease
PL316126A1 (en)Method of obtaining immunoproteins from fractions emerging in a human blood serum fractioning process
WO1996023884A3 (en)Human peroxisome proliferator activated receptors
FR2756827B1 (en) SYNTHETIC BIEPITOPIC COMPOUNDS FOR USE AS STANDARDS IN BIOLOGICAL ASSAYS FOR TROPONIN I
WO2002068615A3 (en)Activation of lymphocyte populations expressing nkg2d using anti-nkg2d antibodies and ligand derivatives
DK673688D0 (en) MONOCLONE ANTIBODIES, HYBRIDOM CELL LINES FOR THE PREPARATION OF THE ANTIBODIES, PROCEDURE FOR THE PREPARATION OF THE ANTIBODIES AND CELLLINES AND USE OF THE ANTIBODIES
WO1987007302A3 (en)MONOCLONAL ANTIBODIES TO HUMAN LYMPHOCYTE IgE RECEPTORS, HYBRIDOMAS PRODUCING SUCH ANTIBODIES, AND KITS FOR USING SUCH ANTIBODIES
CA2180957A1 (en)Cloning and recombinant production of crf receptor(s)
[8]ページ先頭
©2009-2025 Movatter.jp